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ABSTRACT 
 
Background: Advanced-stage ovarian cancer survivors (OCS) often experience a multitude of 
disease symptoms and treatment-related side-effects. Additionally, most OCS are older, have 
comorbidities, are overweight or obese, and report being insufficiently physically active. Ovarian 
cancer survivors may benefit from exercise oncology interventions to reduce symptom-burden, 
manage comorbidities, minimize functional decline and maximize health-related quality of life 
(HRQoL). However, current knowledge gaps regarding the physiological characteristics of OCS 
throughout the entire survivorship spectrum challenge the development of tailored exercise 
interventions. 
Purpose: The overall purpose of this thesis was to provide a more comprehensive physiological and 
activity behavior profile of post-treatment advanced-stage OCS. Specifically, a cross-sectional 
research study was conducted to compare objectively measured activity behavior and physical 
function, body composition and musculoskeletal morphology, self-reported pelvic floor dysfunction 
(PFD) and HRQoL of OCS with age-matched controls. Associations between activity behavior, 
physiological characteristics, PFD and HRQoL for OCS were also investigated.  
Methods: Twenty stage III-IV OCS and 20 age-matched controls underwent objective assessments 
of activity behavior (physical activity and sedentary time via 7-day accelerometry), physical 
function (400-meter walk to assess cardiorespiratory fitness, repeated chair rise to assess lower 
extremity function, 6-meter walking tests to assess gait speed and dynamic balance), muscle 
strength (1-repetition maximum chest press and single leg extension, and handgrip strength), body 
composition (dual-energy x-ray absorptiometry) and musculoskeletal morphology (peripheral 
quantitative computed tomography), and completed questionnaires assessing HRQoL (SF-36) and 
PFD (Australian Pelvic Floor Questionnaire). 
Results: Compared to controls, OCS spent more time/day in prolonged sedentary bouts (i.e., 
uninterrupted sedentary bouts of ≥30 min; p = 0.039), had lower cardiorespiratory fitness (p = 
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0.041) and upper body strength (p = 0.023), had higher areal bone mineral content (p = 0.047) and 
volumetric trabecular density (p = 0.048), but were not different in other measures of body 
composition or musculoskeletal morphology (i.e., all p-values > 0.050). Compared to controls, OCS 
had equivalent self-reported PFD as indicated by combined bladder, bowel and pelvic organ 
prolapse symptoms (p = 0.277), but worse physical HRQoL indicated by a physical composite score 
(p = 0.013). Only 20% (n = 4) of OCS accrued ≥150 minutes/week moderate-and-vigorous physical 
activity (MVPA) in ≥10 min bouts. MVPA time/day in ≥10 min bouts was positively associated 
with cardiorespiratory fitness (p = 0.001), lower extremity function, (p = 0.019), muscle cross-
sectional area (p = 0.035), less PFD (p = 0.038) and physical HRQoL (p = 0.003). Decreased 
physical HRQoL was associated with less MVPA (p = 0.005), more sedentary time (p = 0.047), 
decreased objective physical function (p-values < 0.050) and greater PFD (p = 0.043).  
Conclusion: Post-treatment advanced-stage OCS spent more time in prolonged sedentary bouts, 
had lower cardiorespiratory fitness, upper body strength and physical HRQoL compared to age-
matched controls. The decreased physical HRQoL of this sample of OCS compared to controls and 
its associations with modifiable factors such as MVPA, sedentary time, objective physical function 
and PFD highlights the need for ongoing supportive care and the importance of multidisciplinary 
interventions, including exercise oncology interventions, beyond the completion of first-line ovarian 
cancer treatment. 
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Chapter 1 
INTRODUCTION 
 
BACKGROUND 
Ovarian cancer (OC) is the seventh most common cancer in women worldwide and the most 
fatal gynecological cancer, with an estimated 255,660 new cases and 152,000 deaths in 2015.1 In 
2018, an estimated 1613 women in Australia will be diagnosed with OC, and 1069 women will 
succumb to the disease.2 Common risk factors associated with OC are older age, family history of 
ovarian, breast and/or colorectal cancer, inherited mutations of BRCA1 and BRCA2 genes, use of 
hormone replacement therapy, endometriosis and obesity.3, 4  Factors known to reduce the risk of 
developing OC include oral contraceptive use, full-term pregnancy before age 26, multiple 
pregnancies and gynecological surgery, i.e., hysterectomy and tubal ligation.3, 4  
 Ovarian cancers are often described as a group of heterogeneous diseases of uncertain 
etiology, which can make diagnosis and treatment challenging.5-8 Unfortunately, the large majority 
of OC cases (between 70% and 75%) are diagnosed at an advanced stage when the tumor has 
already spread beyond the ovaries (stage III and IV).9  Two of the main reasons for this are the lack 
of effective screening tests for OC coupled with diffuse early symptoms.10  Early signs and 
symptoms of OC, most commonly abdominal and pelvic pain, bloating, difficulty eating or feeling 
full quickly, and urinary frequency or urgency, are often vague and similar to symptoms of other 
more common and often less serious health conditions.11 The five-year survival rates for women 
with stage III and IV OC are 39% and 17%, respectively.12 
Standard first-line treatment for advanced OC involves primary debulking surgery (PDS) to 
remove as much of the tumor as possible, followed by adjuvant carboplatin-paclitaxel combination 
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chemotherapy.10 Optimal tumor debulking (i.e., removal of all visible tumor) is considered the most 
important factor associated with prolonged OC survival.13, 14 Whether a tumor can be optimally 
debulked depends on factors such as the patient’s age, co-morbidities, performance status, disease 
stage, disease burden and location of metastatic sites.15 In cases where optimal debulking seems 
unlikely, chemotherapy administered prior to debulking surgery, or neoadjuvant chemotherapy 
(NACT), is an alternative treatment option increasingly being utilized worldwide.16 Although most 
women respond well to first-line treatment, 70% of women with advanced-stage OC and up to 30% 
of those with early-stage cancers will eventually relapse and require further treatment.17 18 Due to 
the burden of advanced disease and often prolonged treatment, ovarian cancer survivors (OCS) 
frequently experience persistent symptoms and side-effects such as fatigue, poor sleep quality, 
peripheral neuropathy, cognitive impairment, sexual dysfunction and psychological distress.19-23 
Many of these symptoms and side-effects have been associated with reduced quality of life.23, 24 
Complicating the burden of advanced cancer and associated treatments, 50% of OCS are 63 
years and older,25 75% have concurrent comorbidities26-28 and 15-30% are obese (i.e., BMI ≥30).26, 
29-33 Furthermore, between 50% and 80% of OCS report being insufficiently physically active (i.e., 
engage in <150 minutes of moderate and vigorous physical activity per week).26, 27, 29, 34 Limited 
research, most of which include mixed samples of gynaecological cancer survivors, suggest 
impaired cardiorespiratory fitness and physical function in this cancer population.34-36 Ovarian 
cancer survivors may benefit from supportive care interventions to reduce symptom-burden, 
manage comorbidities, minimize functional decline and maximize health-related quality of life. 
Considerable research has demonstrated multiple benefits of physical activity and exercise 
after a cancer diagnosis.35, 37-39 Physical activity is commonly defined as “any bodily movement 
produced by skeletal muscles that results in energy expenditure” and includes occupational, 
household and sport activities, and exercise. Exercise is a subset of physical activity and refers to 
planned, structured and repetitive activity with the purpose to improve or maintain physical fitness 
and health.40  However, the majority of this evidence, as well as current physical activity (PA) and 
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exercise oncology guidelines endorsed by professional organizations such as the American College 
of Sports Medicine and American Cancer Society, are primarily based on research over the past two 
decades involving breast and prostate cancer survivors.37 Research evidence for the benefits of PA 
and exercise in OC is limited to small, non-randomized studies.41-43 To inform the design of OC-
specific exercise oncology interventions for both research and clinical settings, a more 
comprehensive activity behavior and physiological profile of OCS is needed. A challenge posed by 
most existing OC research is the notable lack of objectively measured data describing body 
composition, activity behaviors (i.e., PA and sedentary behavior) and physical function. 
Furthermore, information on pelvic floor dysfunction (PFD), a recognized barrier to physical 
activity and exercise44, 45 and associated with reduced health-related quality of life (HRQoL) in 
women globally,46, 47 is limited to studies with mixed samples of gynecological cancer survivors. 48, 
49 Also, most current OC studies include heterogeneous samples of participants including women 
with different stages of cancer, often on different treatments and at different time points in the 
cancer trajectory. Particularly lacking is information regarding the post first-line treatment status of 
advanced OCS. 
 
RESEARCH SIGNIFICANCE 
The need for tailored supportive care interventions such as exercise prescription to reduce 
the impact of OC and its treatment is often highlighted in research studies.24, 26, 33, 41, 50-52  However, 
a comprehensive picture of objective activity behaviors and physical function, muscle strength, 
body composition, musculoskeletal morphology and pelvic floor symptoms in OCS is not available. 
This presents a challenge for the design of tailored exercise intervention studies and exercise 
oncology guidelines. Results from this study will provide a more comprehensive activity behavior 
and physiological profile of advanced-stage OCS to empirically inform the design and application 
of OC-specific exercise oncology interventions for both research and clinical practice. 
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RESEARCH PURPOSE AND OVERVIEW 
The purpose of this research is to provide a comprehensive activity behavior and 
physiological profile of post-treatment advanced-stage OCS. Chapter Two is a published narrative 
review of existing literature relating to the physiological characteristics of OCS in terms of 
treatment-related side-effects, concurrent comorbidities, body weight and composition, physical 
fitness and function, and self-reported physical activity behavior.53 In Chapters Three and Four we 
present results of an original cross-sectional research study conducted with 20 advanced-stage OCS 
who had received either neoadjuvant chemotherapy treatment and interval debulking surgery, or 
primary debulking surgery and adjuvant chemotherapy treatment. More specifically, in Chapter 
Three we describe objectively measured activity behaviors (PA and sedentary behavior) and 
physiological characteristics (physical function, muscle strength, body composition and 
musculoskeletal morphology) of OCS compared to age-matched controls (Manuscript under review, 
International Journal of Gynecological Cancer, Manuscript No. IGC-D-17-00571). In Chapter Four 
we compare HRQoL and self-reported PFD of OCS with age-matched controls and examine 
correlations between HRQoL and PFD (Manuscript prepared for submission to Supportive Care in 
Cancer, October 2017). Finally, in Chapter Five we provide an overall critical discussion of major 
findings and conclusions of our narrative review and experimental chapters, with recommendations 
for future research. 
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ABSTRACT  
Objective: Physical activity has become increasingly important in supportive cancer care. 
However, physical activity and exercise guidelines for ovarian cancer survivors remain generic. The 
aim of this narrative review is to summarize existing data regarding the physiological characteristics 
(treatment-related adverse effects, concurrent comorbidities, body weight and composition, physical 
fitness and function, and physical activity behavior) of ovarian cancer survivors to further 
understanding of their cancer-specific physical activity and exercise needs. We also highlight gaps 
in the current knowledge base. 
Methods: We undertook a narrative review of current literature on the physiological status of 
ovarian cancer survivors. We defined physiological status as treatment-related adverse effects, 
concurrent comorbidities, body weight and composition, physical fitness and function, and physical 
activity behavior.  
Results: In addition to disease- and treatment-related symptoms and adverse effects, the majority of 
ovarian cancer survivors have comorbidities, which may adversely affect treatment effectiveness 
and safety, as well as survival. Despite high overweight and obesity rates, a large percentage of 
women are malnourished at diagnosis, with potentially compromised muscle mass and muscle 
density. Low muscle density at diagnosis and loss of muscle mass during treatment may be 
associated with worse survival outcomes. A small number of studies have observed impaired 
physical function and cardiorespiratory fitness in ovarian cancer survivors. The majority of ovarian 
cancer survivors are insufficiently active or sedentary. 
Conclusion: Our review suggests that ovarian cancer survivors could benefit from physical activity 
and exercise oncology interventions aimed at addressing detrimental changes to physiological status 
due to disease and treatment. However, current knowledge gaps regarding the physiological 
characteristics of ovarian cancer survivors throughout the entire survivorship spectrum challenges 
the development of tailored exercise intervention studies and exercise oncology guidelines.    
Key Words: Ovarian cancer, Comorbidities, Body composition, Physical fitness, Physical activity 
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INTRODUCTION 
Ovarian cancer  (OC) is the seventh most common cancer in women worldwide and the 
most lethal gynecological malignancy, with an estimated 255,660 new cases and 163,765 deaths in 
2015.1 Due to lack of effective screening tests and the non-specific nature of symptoms, 70-75% of 
women with OC receive the diagnosis at an advanced stage (stages III-IV).2 Standard treatment for 
OC involves either primary surgery followed by adjuvant paclitaxel-carboplatin combination 
chemotherapy, or neoadjuvant chemotherapy with interval debulking surgery.3 Although most 
women initially respond well to treatment, recurrence rates are high, with 70% of advanced-stage 
OCs and up to 30% of early-stage OCs eventually relapsing and requiring further treatment.4, 5 The 
aim of treatment after recurrence is to control the disease and disease-related symptoms, limit 
treatment toxicities and prolong time to disease progression and death, whilst optimizing quality of 
life.2 Identifying appropriate, targeted adjuvant interventions to reduce symptom-burden and 
minimize functional decline and disability are crucial in the ongoing care of OC survivors.   
Physical activity is defined as “any bodily movement produced by skeletal muscles that 
results in energy expenditure.” Exercise as a subset of physical activity refers to planned, structured 
and repetitive activity with the purpose to improve or maintain physical fitness and health.6 Physical 
activity is important in the management of many chronic conditions and the prescription of exercise 
as “medicine” should be integral in the treatment of chronic diseases such as cancer.7  The term 
“cancer survivor” is based on the National Comprehensive Cancer Network definition and refers to 
people living with cancer, from the time of diagnosis, through all disease stages, until death.8  
Higher physical activity levels in cancer survivors have been associated with reduced disease and 
treatment adverse effects, increased physical and emotional well-being,9 as well as reduced risk of 
recurrence, cancer-specific and all-cause mortality in certain cancer groups.10, 11 Since the American 
College of Sports Medicine published initial guidelines and recommendations for exercise 
oncology12 other professional and cancer organizations (e.g. American Cancer Society, National 
Comprehensive Cancer Network) have endorsed the concept that cancer survivors should avoid 
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physical inactivity and, if possible, undertake 150 minutes of aerobic exercise a week and twice-
weekly resistance exercises (REs).13 However, most of these recommendations have been based on 
research over the past 2 decades involving primarily breast and prostate cancer survivors. As a 
result, there is a logical and clinical requirement to understand and identify gaps in knowledge, 
particularly for understudied cancers such as OC.14 Research to help tailor physical activity 
guidelines and exercise interventions to specific cancer groups is crucial to maximize the impact of 
physical activity and exercise interventions in clinical and research settings and to further advance 
the field of exercise oncology.  
The purpose of this review is to synthesize published literature on treatment-related adverse 
effects, concurrent comorbidities, body weight and composition, physical function and fitness, and 
physical activity behavior of OC survivors to provide a more complete physiological profile of this 
cancer group. A secondary aim is to highlight key gaps in knowledge to inform future research. 
Improved knowledge of the multifaceted challenges faced by OC survivors will support the 
development of exercise oncology recommendations specifically for OC survivors. In addition, it 
will provide a scientific basis for the design and application of tailored exercise interventions in 
both research and clinical settings (Fig 1).  
METHODS 
Information for this review was obtained by searching the PubMed, Medline, CINAHL and 
SPORTDiscus databases for relevant articles in English published between January 1970 and 
December 2016 pertaining to treatment-related adverse effects, comorbid conditions, body weight, 
body composition, physical function and fitness, and exercise and physical activity levels in OC 
survivors. Search terms included “OC,” “ovarian neoplasms,” “treatment” (side-effects, symptoms), 
“comorbidities,” “BMI,” “body composition,” “physical fitness” (muscular strength, muscular 
endurance, cardiorespiratory fitness, cardiovascular fitness), “physical function” (grip strength, gait 
speed, walking speed, mobility, balance), and “physical activity” (physical activity behavior, habits, 
participation, levels, exercise). Reference lists of relevant papers were also searched. Review 
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articles, randomized controlled trials, cross-sectional studies and observational cohort studies 
published in peer-reviewed journals as full-text articles were reviewed by CS. Abstracts, case 
reports, editorials and study protocols were excluded. 
RESULTS 
Treatment-related Adverse Effects  
The cumulative adverse effects of surgery, chemotherapy, and targeted therapy can have a 
debilitating impact on the lives of OC survivors, both during and following treatment.15   
Acute adverse effects commonly reported during OC treatment include fatigue, pain, 
appetite loss, constipation, diarrhea, nausea, vomiting and dyspnea. Abdominal discomfort (pain, 
bloating, cramping and indigestion), insomnia, neuropathy, sexual dysfunction, weight gain, and 
weight loss are also common.16 Women with advanced stage or recurrent OC who are treated with 
bevacizumab in addition to chemotherapy can experience hypertension, proteinuria, wound-healing 
complications, thrombotic events, and gastrointestinal perforation.17, 18  
Chronic adverse effects continue to affect at least 20% of disease-free OC survivors 
regardless of stage of disease.19-21 Fatigue is the most prevalent physical burden for women with 
active disease.22 Poor sleep quality, chemotherapy-related cognitive impairment and peripheral 
neuropathy affect 60% to 70% of survivors of stages I to IV OC at least 1 year after diagnosis.23-25 
Gastrointestinal issues such as constipation, diarrhea, indigestion and flatulence remain burdensome 
in 16% to 47% of OC survivors years after treatment completion.24, 25 The majority of survivors 
report no sexual activity 3 years or more after treatment completion,26, 27 and more than 70% of 
women who remain sexually active experience sexual discomfort.26 Although sexual and 
gastrointestinal dysfunction in this group of cancer survivors is well documented, data regarding the 
prevalence, severity and impact of pelvic floor dysfunction are limited. Such data are crucial for the 
design of OC-specific exercise interventions.  
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About 20% of all OC survivors will experience anxiety and depression at some point in their 
cancer trajectory.28 Fear of recurrence is a major cause of psychological distress for survivors of all 
ages, irrespective of disease stage or treatment received.29 Depressive symptoms are strongly 
correlated to physical symptoms, fatigue, poor sleep quality, physical function and quality of life.23, 
30, 31
 More research is needed to determine if, and how, these physical and psychological symptoms 
and adverse effects change over time and whether differences are treatment related (eg, neoadjuvant 
vs adjuvant chemotherapy). 
Concurrent Comorbidities 
Cancer survivors are more likely to have multiple chronic medical conditions than age-
matched control subjects.32 Although prevalence rates vary, hypertension, arthritis, 
hypercholesterolemia, thyroid disorders and musculoskeletal issues are commonly reported in OC 
survivors.20-22, 24, 33-35 Approximately 75% of OC survivors self-reported 1 or more comorbidities in 
separate cross-sectional survey studies.21, 34, 36  By contrast, 1 or more comorbidities were identified 
in only 25% of survivors when information from cancer registries was used.37 This discordance may 
be due to response bias and/or ascertainment bias, which are inherent in such studies. The 
prevalence of comorbidities does not appear to differ significantly between survivors of early- and 
advanced-stage OC,38 although obese survivors are more likely to have comorbidities.39 Research 
suggests that women with comorbidities are less likely to receive standard cytoreductive surgery 
and/or combination chemotherapy,40 and have poorer survival outcomes.41 Thus, knowledge about 
the status and severity of concurrent comorbidities throughout the survivorship spectrum, as well as 
a better understanding of the impact of concurrent medications on OC treatment and treatment 
toxicity, is crucial, especially in light of the confirmed benefit of exercise to manage chronic 
conditions.7 
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Body Weight 
Obesity (as indicated by a body mass index [BMI] of ≥30 kg/m²) is associated with a higher 
risk of recurrence and mortality in many cancer groups.42 Obesity rates in OC range between 15% 
and 30%,36, 43-47 however, findings on the impact of obesity on OC prognosis have been 
inconsistent. A systematic review and meta-analysis by Bae et al48 found no association between 
BMI at time of diagnosis and survival. In contrast, a recent meta-analysis, which included 12,390 
OC survivors from 21 studies, concluded that obesity at or before diagnosis negatively affects 
survival in low-grade serous, endometrioid and high-grade serous OCs, but not in clear-cell or 
mucinous cancers.49 This may reflect the heterogeneity of studies in these meta-analyses. While the 
impact of obesity on survival after an OC diagnosis has not been fully elucidated,48, 50 increased 
BMI may adversely affect treatment effectiveness and safety. Obese women are more likely to 
experience suboptimal chemotherapy dosing, postsurgical complications50 and hospital 
readmissions.51 Complications that delay or disrupt adjuvant chemotherapy treatment may have a 
negative impact on quality of life, and potentially survival.50 The adverse effects of obesity on 
treatment outcomes and possibly survival warrants further investigation. For example, studies 
investigating the impact of increased physical activity or participation in structured and regular 
exercise interventions on BMI after an OC diagnosis are needed. 
While several studies have addressed the impact of obesity on OC outcomes, information 
about the prevalence and impact of weight loss during the disease trajectory, and underweight status 
(as indicated by a BMI <18.5 kg/m²) is limited. Data suggest that 40% to 60% of women with 
advanced-stage OC lose weight during adjuvant chemotherapy.45, 52 However, the relationship 
between weight loss during treatment and changes in body composition has yet to be elucidated. In 
addition, how weight loss impacts treatment and whether weight loss continues after completion of 
treatment remains unclear. Low rates of underweight women (2%-9%) have been reported across all 
disease stages,53-56 and conclusions regarding the impact of underweight status on survival are 
conflicting. Separate studies associate BMI of less than 18.5 kg/m² at diagnosis in all disease 
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stages,55 and after treatment completion in advanced stage,53 with increased mortality. Conversely, a 
recent meta-analysis found no association between underweight status and disease stage or survival, 
but concluded that more data are needed to confirm this finding.56 More research is needed to 
delineate the impact of overweight or underweight status, as well as weight change in all disease 
stages throughout the survivorship spectrum. 
The relationship between OC survivors’ body weight and nutritional status is complex. 
While less than 10% of women are underweight,56 30% to 67% are malnourished at diagnosis, 
based on nutrition assessment tools such as the Patient-Generated Subjective Global Assessment 
and the Nutritional Risk Index.44, 52, 57, 58 The presence of ascites and a high body fat percentage at 
any time point will “inflate” BMI values and mask muscle wasting, a consequence of 
malnourishment.59 In addition to BMI, body composition measures can provide much needed 
objective data to identify OC survivors with low muscle mass and/or excess body fat in need of 
dietary and exercise interventions. 
Body Composition  
Low muscle mass may be associated with increased treatment toxicity and mortality in 
cancer survivors.60 To date only a small number of studies have examined body composition and 
muscle quality in OC survivors. Low muscle mass, indicated by a skeletal muscle index below 39.0 
cm²/m², was observed in 45% of a large cohort of women with newly diagnosed advanced-stage 
OC.61 The skeletal muscle index was calculated by dividing skeletal muscle area (in centimeters 
squared), measured preoperatively with computed tomography at the level of the third lumbar 
vertebra, by the height squared (in meters squared). However, current data do not confirm an 
association between low muscle mass at diagnosis and OC survival.46, 59, 61 An important finding by 
Rutten et al.59 is the association of skeletal muscle loss during neoadjuvant chemotherapy with 
decreased survival, although this finding requires further confirmation. 
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Recent evidence suggests that muscle density, more so than muscle mass, could be an 
important prognostic factor in OC. Preliminary evidence indicates a positive association between 
skeletal muscle attenuation (a measure of muscle density, with lower values indicating a higher 
muscle fat content) and survival in certain cancer groups.62 Low skeletal muscle attenuation at 
diagnosis was associated with decreased overall survival in 2 separate OC studies.46, 61 The findings 
of these retrospective studies require validation in future randomized controlled trials. 
In addition to potential changes in muscle and fat content, OC survivors may experience 
alterations in bone mineral density. However, the prevalence of osteopenia and osteoporosis are 
seldom reported in OC studies. Although bone loss has been observed in pre- and postmenopausal 
OC survivors in the first year after diagnosis,63-65 these studies included gynecological cancer 
survivors with only small samples of OC survivors (n = 30, 15 and 12, respectively). Given that 
bone-related comorbidities (eg, osteoporosis) could have a significant impact on exercise 
prescription, more research is needed to understand the prevalence of, and changes in, bone mineral 
density throughout the OC trajectory.  
Physical Fitness and Function  
Physical fitness is historically defined as “the ability to carry out daily tasks with vigor and 
alertness, without undue fatigue.” The term encompasses several measurable components, including 
cardiorespiratory capacity and endurance, muscular strength and  endurance, body composition, and 
flexibility,6 all of which potentially affect physical function in cancer survivors.66 Information 
regarding OC survivors’ cardiorespiratory and muscular fitness is lacking, with only a limited 
number of nonrandomized exercise intervention studies reporting these measures.67, 68 Data from a 
small cross-sectional study suggest impaired cardiorespiratory fitness in gynecological cancer 
survivors many years after diagnosis, when compared with age-matched control subjects.69 This 
finding is important considering the strong inverse association between cardiorespiratory fitness and 
cancer mortality, independent of adiposity level.70  
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Impairments in physical function predict disability, institutionalization and mortality in 
older people71 and may predict mortality in cancer survivors.72 Research regarding physical 
function in OC survivors is limited and mostly measures self-reported physical function with 
quality-of-life instruments. Only 10% of a small sample of long-term survivors of stages III to IV 
OC without evidence of recurrent disease reported functional limitations.19 In contrast, impaired 
physical function was reported by 38% of more than 5000 gynecological cancer survivors, which 
included 922 OC survivors, at least one year since diagnosis. Participants were considered 
functionally impaired if they responded “yes” to 1 or both questions regarding limitations in 
activities and use of special equipment due to health problems.73 Self-rated functional impairment in 
OC survivors is associated with lower physical activity levels,36, 73 older age,15 obesity,36 
comorbidities, fatigue,74 peripheral neuropathy,35 and increased psychological distress.75 Physical 
function has seldom been objectively measured in OC research. One study found an association 
between physical function, measured objectively using the Short Physical Performance Battery and 
usual gait speed, and mortality in a mixed sample of older gynecological cancer survivors,76 
indicating a need for more quantitative data regarding physical function in OC survivors.  
Considering evidence from other cancer groups such as breast and prostate cancer,12 
exercise interventions are likely to be an effective strategy to improve physical fitness and function 
in OC survivors. However, such strategies need to be tested in OC survivors in adequately powered 
prospective, controlled clinical trials.   
Physical Activity Participation   
Ovarian cancer survivors’ physical activity participation rates are low.  In comparison to 
27% of women and 35% of women in high-income countries, worldwide,77 50% to 80 % of OC 
survivors reported insufficient physical activity levels (ie, <150 minutes of moderate and vigorous 
physical activity per week) or a sedentary lifestyle (ie, no moderate and vigorous physical activity 
per week) after treatment completion.34, 36, 43, 73 Research suggests that most women decrease 
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physical activity levels after diagnosis,78 and many do not return to pre-diagnosis levels.79 
Interestingly, OC survivors’ participation rates in RE (ie, exercise that involves performing sets of 
repeated movements against a resistance, such as lifting weights)80 have not been previously 
reported. However, considering research in other cancer survivor populations, where participation 
in sufficient RE (ie, ≥ 2 sessions/wk for ≥ 30 minutes) is only 10%,81 participation is likely to be 
low. Information regarding OC survivors’ participation rates in RE and the feasibility of RE 
programs is important, especially considering the positive effects of RE on muscular strength and 
body composition in cancer survivors.82 
Higher levels of physical activity after a cancer diagnosis are associated with a reduced risk 
of cancer-specific and all-cause mortality in breast, colorectal and prostate cancer.10, 11 The 
association between physical activity after an OC diagnosis and mortality remains unclear, although 
prediagnostic physical activity appears to affect survival in this cancer group.83 Ovarian cancer 
survivors who report being more physically active have reduced symptom burden, improved 
physical fitness and function, and a better quality of life.34, 36, 67, 68, 84 However, most studies 
investigating physical activity in OC survivors are cross-sectional in design, which precludes 
inferring conclusions about causality and indicates a need for future prospective randomized 
controlled trials. In addition, limitations of self-reported physical activity, such as overreporting,85 
must be considered when interpreting the results of these studies. Objective assessment of physical 
activity should be included in future studies to provide more comprehensive, valid, and reliable data 
about physical activity participation and patterns of sedentary behavior.  
 Ovarian cancer survivors often express interest in participating in physical activity 
programs,86, 87 but frequently report a combination of demographic, medical and motivational 
barriers to physical activity and exercise participation.78 Demographic and medical barriers include 
older age, higher BMI, shorter time since diagnosis, or current disease.88 The most commonly 
reported barriers to exercise are fatigue (37.8%), exercise not being part of usual routine (34.7%), 
and lack of self-discipline (32.6%).78 
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SUMMARY AND AREAS FOR FUTURE RESEARCH 
Women with a diagnosis of OC often experience a range of physical and psychological 
symptoms and adverse effects during and after cancer treatment, regardless of disease stage. In 
addition, about 75% of women have self-reported comorbidities,21, 34, 36 and 15% to 30% are 
obese,36, 43-47 both of which may adversely affect treatment and survival. Despite high overweight 
and obesity rates, a large percentage of women are malnourished at diagnosis, with potentially 
compromised muscle mass and muscle density. This is particularly important in OC survivors 
because low muscle density at diagnosis and loss of muscle mass during treatment may be 
associated with worse survival outcomes. A small number of studies have observed impaired 
physical function and cardiorespiratory fitness in OC survivors. Despite high levels of interest in 
physical activity programs, and some evidence for an association between physical activity and 
physical well-being, 50% to 80% of OC survivors are insufficiently active or sedentary because of 
numerous demographic, medical and behavioral barriers.34, 36, 43, 73 Because of a current lack of 
scientific knowledge, physical activity and prescription of regular and structured exercise might not 
be optimally promoted by the OC care team. 
The greatest challenge for the design and application of evidence-based exercise oncology 
guidelines in OC care is the heterogeneity of existing studies. To date, most studies have included 
women with all stages and grades of cancer, often on different treatment regimens and at different 
time points in the cancer trajectory. Furthermore, the majority of studies reporting on comorbidities, 
body weight and body composition, physical fitness and function, and physical activity habits are 
cross-sectional or retrospective in nature, and do not provide information on changes in 
physiological status of OC survivors over the course of the cancer trajectory. A further challenge is 
the notable lack of objectively measured data describing physical activity behavior, physical fitness 
and physical function.  
Future research should aim to provide evidence-based objective information describing the 
physiological characteristics of OC survivors throughout the entire survivorship spectrum, with 
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careful consideration of potential differences due to disease stage, treatment regime or survivorship 
stage. Such information will provide a better understanding of the impact of OC and its treatment 
and will empirically inform the design and application of OC-specific exercise oncology guidelines, 
thus maximizing the potential impact of exercise medicine in both clinical and research settings.
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Comorbidities 
-High rates 
-hypertension, arthritis, hypercholesterolemia, 
thyroid disorders and musculoskeletal issues  
Physical fitness and function 
-Decreased cardiorespiratory fitness* 
-Decreased physical function* 
Physical activity participation 
-Low rates 
-High interest in physical activity programs, but 
unmet needs 
Treatment-related side-effects 
-Fatigue, peripheral neuropathy, poor sleep 
quality, cognitive and sexual dysfunction common 
-Can persist after treatment completion 
Body composition 
-Decreased muscle mass and muscle density* 
Reduced symptom burden 
associated with higher physical 
activity rates* 
Sub-optimal treatment* 
Decreased physical function* 
Decreased survival* 
Body weight 
-High overweight and obesity rates  
Sub-optimal treatment* 
Decreased physical function* 
Decreased survival* 
Decreased survival* 
 No evidence 
Low physical activity rates 
associated with:  
 -  Increased symptom burden* 
 -  Decreased physical fitness* 
 -  Decreased physical function* 
 -  Decreased quality of life* 
Exercise interventions with appropriately 
prescribed resistance and cardiorespiratory 
exercise could assist to: 
- Reduce treatment-related side-effects 
- Better manage comorbidities 
- Positively alter body composition by:  
-Reducing fat mass 
-Increasing muscle mass and density 
- Increase muscle strength and endurance 
- Increase cardiorespiratory fitness 
- Increase physical function 
- Reduce symptom burden 
- Increase physical activity levels 
- Increase quality of life 
Figure 1. Opportunities for exercise oncology interventions in OC care based on current evidence  
    (* limited data) Physical activity refers to minutes of moderate and vigorous exercise/week. 
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Chapter 3 
OBSERVATIONAL STUDY 
 
 
 
“Activity behaviors and physiological characteristics of women with advanced-stage 
ovarian cancer: a comprehensive cross-sectional investigation”  
 
 
Schofield C, Newton RU, Galvão DA, Cohen PA, McVeigh JA, Hart NH, Mohan GR, Tan J, 
Salfinger SG, Straker LM, Peddle-McIntyre CJ. International Journal of Gynecological Cancer. 
Under review. 
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ABSTRACT  
Objectives: Ovarian cancer survivors (OCS) experience many disease and treatment adverse 
effects. Yet, the impact of ovarian cancer and its treatment on objective activity behaviors and 
physiological status has not been comprehensively examined. The purpose of this study was to 
compare objectively measured activity behaviors and physiological characteristics of advanced-
stage OCS to age-matched controls. Secondarily, OCS who underwent different treatment regimens 
were compared. 
Methods: Twenty stage III-IV OCS and 20 controls completed assessments of activity behaviors 
(7-day accelerometry), physical function (400-meter walk as indicator of cardiorespiratory fitness, 
repeated chair rise, 6-meter walking tests), muscle strength (1-repetition maximum and hand grip), 
body composition (dual-energy x-ray absorptiometry) and musculoskeletal morphology (peripheral 
quantitative computed tomography).  
Results: Compared to controls, OCS spent more time/day in prolonged sedentary bouts (p = 0.039), 
had lower cardiorespiratory fitness (p = 0.041) and upper body strength (p = 0.023), had higher 
areal bone mineral content (p = 0.047) and volumetric trabecular density (p = 0.048), but were not 
different in other measures of body composition, nor in muscle morphology (p-values > 0.050). 
Appendicular lean mass was significantly higher for women who received neoadjuvant 
chemotherapy compared to those who received adjuvant chemotherapy (p = 0.045). Only 20% (n = 
4) of OCS accrued ≥150 minutes/week moderate-and-vigorous physical activity (MVPA) time in 
≥10 min bouts. MVPA time/day in ≥10 min bouts was associated with cardiorespiratory fitness (p = 
0.001), lower extremity function (p = 0.019) and muscle cross-sectional area (p = 0.035). 
Conclusion: Post-treatment OCS spent more time in prolonged sedentary bouts and had lower 
cardiorespiratory fitness and upper body strength compared to controls. MVPA was associated with 
physical function and muscle cross-sectional area. Future studies should test the efficacy of exercise 
interventions to increase MVPA, reduce sedentary behavior, and increase cardiorespiratory fitness 
and muscle strength in OCS. 
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INTRODUCTION 
Ovarian cancer (OC) is the most lethal gynecological malignancy with an estimated 255,660 
new cases and 163,765 deaths worldwide in 2015.1 Most cases are diagnosed at an advanced stage.2 
Standard first-line treatment for OC involves primary debulking surgery (PDS) followed by 
adjuvant carboplatin-paclitaxel combination chemotherapy. Neoadjuvant chemotherapy (NACT) 
with interval debulking surgery is an alternative treatment for women with stage IV disease, 
unresectable bulky tumors and poor performance status.3 Approximately 70% of women diagnosed 
with advanced OC will relapse and require additional treatment.4 
Beyond the burden of OC, most ovarian cancer survivors (OCS) have comorbidities5, 6 and 
are overweight or obese.6-8 Between 50% and 80% report insufficient participation in physical 
activity (PA),5, 6, 8, 9 with initial reports suggesting impaired physical function in this population.9, 10 
However, most studies to date have assessed PA and physiological characteristics with self-report 
measures in heterogeneous groups of OCS involving women with diverse stages of disease and 
treatment regimens across varied time-points in the disease trajectory.11 As a result, consequences 
of OC and its treatment on objectively measured activity behaviors (PA and sedentary behavior 
[SB]), physical function, body composition, and muscle morphology (cross-sectional area [CSA] 
and density) remain largely undefined.  
Due to a paucity of information on objectively measured activity behaviors in OC research, 
the relationship of objectively measured PA and sedentary behavior with physical function and 
body composition in this cancer population is also poorly understood. Existing research indicates a 
positive association between objectively measured moderate and vigorous PA (MVPA) and 
physical function in colon cancer survivors,12 while objective measures of MVPA is inversely 
associated with waist circumference in prostate cancer survivors.13 Objectively measured sedentary 
time has been inversely associated with physical function in long-term cancer survivors14 and 
performance status and survival in patients with malignant pleural effusion.15  Considering the 
discrepancy between self-reported and objectively measured PA and sedentary time,16, 17 
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quantification of OCS’ activity behaviors and physiological characteristics, and of the association 
between them, is critical for development and testing of targeted interventions aimed at improving 
patient outcomes. 
In this cross-sectional study we compared objectively measured activity behaviors and a 
range of objective physiological measures in a cohort of women with advanced-stage epithelial OC 
following first-line treatment to age-matched controls. We also examined potential differences in 
advanced-stage OCS treated by NACT and interval debulking surgery compared to women treated 
by PDS and adjuvant chemotherapy. Lastly, we explored associations of objectively measured 
activity behaviors with objective measures of physical function, body composition and muscle 
morphology in OCS.   
METHODS 
Setting and Participants 
The study was conducted at the Exercise Medicine Research Institute at Edith Cowan 
University and St John of God Subiaco Hospital in Perth, Western Australia. Ethical approval was 
granted by the Edith Cowan University (Ref. No. 12511, 23/4/2015) and St John of God Health 
Care Human Research Ethics Committees (Ref. No. 815, 12/6/2015). Eligibility criteria were: 
histologically confirmed stage III–IV epithelial OC, 3-24 months post completion of treatment, ≥18 
years of age, approval from the treating oncologist or general practitioner, able to walk 400 meters, 
proficient in English, no existing or suspected bone metastases, no acute illness or any 
musculoskeletal, cardiovascular or neurological disorder that could put the participant at risk during 
exercise testing. The same non-cancer eligibility criteria applied for the control group. Written 
informed consent was obtained from all participants. 
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Recruitment  
Eligible patients were identified via consulting rooms of three gynecologic oncologists and 
were informed of the study by phone or letter. The principle investigator (CS) phoned patients to 
confirm interest and eligibility. Control group participants were recruited via snowball sampling, 
from staff at a local university and hospital, and from the wider community. A study information 
pack was posted to all eligible participants.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Participant recruitment flowchart 
 
Ovarian cancer group: 
86 post-treatment stage III-
IV ovarian cancer survivors 
identified  
Non-cancer control group: 
35 female volunteers with no 
previous cancer diagnosis 
identified 
Reasons for ineligibility (n=42) 
Uncontactable (n=17) 
Recurrent disease (n=12) 
Medical contraindications (n=5) 
Deceased (n=4) 
On treatment (n=4) 
Reasons for ineligibility (n=4) 
Outside identified age range (n=4) 
  
44 stage III-IV ovarian cancer 
survivors eligible 
  
31 women with no previous 
cancer diagnosis eligible 
Reasons for non-enrolment (n=24) 
Not interested (n=12) 
Lives too far (n=6) 
“Too old” (n=2) 
Family or work commitments (n=3) 
Travelling (n=1) 
  
Reasons for non-enrolment (n=11) 
Unable to age match to 
experimental participant (n=8) 
Withdrew interest (n=3) 
20 ovarian cancer survivors 
enrolled  
  
20 women with no previous 
cancer diagnosis enrolled  
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Outcome Measures 
Demographic and medical data regarding participants’ age, marital status, education level, 
employment status and medical history were obtained by self-report questionnaire. Additional 
information regarding cancer diagnosis and treatment were collected from OCS. All 
anthropometric, body composition and objective functional data were collected at the Exercise 
Medicine Research Institute by one investigator (CS). Participants attended two sessions (i.e., a 
familiarization session followed by a testing session) no less than six, but no more than 14 days 
apart.  
Anthropometric Measures 
Height and body weight, measured by a digital measuring-and-weighing station (Model 763, 
Seca, Hamburg, Germany), were used to calculate body mass index (BMI; kg/m²). Waist and hip 
circumference were measured at the narrowest part of the torso or between the iliac crest and 12th 
rib, and the maximal circumference of the hip.18 Waist-to-hip ratio was calculated by dividing waist 
circumference by hip circumference. 
Physical Activity and Sedentary Behavior 
Objective PA and sedentary time were measured with a hip-worn tri-axial accelerometer 
(ActiGraph GT3X+, ActiGraph Corp, FL, USA). Participants were asked to wear the accelerometer 
continuously for seven days, except when bathing/showering or participating in water-based 
activities. The GT3X+ was programmed to record raw data at a frequency of 30Hz, which were 
later reduced to vertical axis movement counts/60 s epoch 
for the purpose of our analyses. Accelerometer data were downloaded with Actilife (Version 6.13.3, 
ActiGraph Corp, FL, USA) and processed in SAS (Version 9.3, SAS Institute Inc., NC, USA). An 
automated algorithm was used to identify awake wear time.19 To render days of data collection 
valid, a minimum awake wear time of 600 minutes (10 hours) was required.20 A minimum of four 
valid days was required for analysis. Activity counts were categorized as: sedentary (<100 
38 
 
counts/minute [cpm]), light intensity PA (LIPA; 100-<1952 cpm), moderate intensity PA (1952-
<5275 cpm), vigorous intensity PA (≥5275 cpm), or moderate and vigorous PA (MVPA; ≥1952 
cpm).21, 22 Participants were categorized as meeting (i.e., ≥150 minutes of MVPA/week) or not 
meeting (i.e., <150 minutes of MVPA/week) current PA guidelines for cancer survivors.23 
Prolonged sedentary bouts were defined as uninterrupted sedentary bouts of ≥30 minutes.15, 24 
Physical function and muscle strength 
Measures of physical function included: (1) 400-meter walk as an indicator of 
cardiorespiratory fitness,25 (2) repeated chair rise to assess lower extremity function,26 (3) 6-meter 
usual pace walk to assess gait speed during daily activities, (4) 6-meter fast pace walk to assess 
fastest self-selected gait speed and, (5) 6-meter backwards walk to assess dynamic balance.27, 28 
With the exception of the 400-meter walk test, each test was performed three times, the fastest of 
which was used for analysis. Measures of muscle strength included: (1) one repetition maximum (1-
RM) chest press and single-leg extension to measure dynamic upper and lower body muscle 
strength, (2) handgrip strength test to assess isometric grip strength. Relative strength was 
calculated by dividing absolute strength by body weight. 
Body composition and muscle morphology 
Body composition was measured by dual-energy x-ray absorptiometry (DXA, QDR-1500, 
Hologic Discovery A, Waltham, MA). Participants’ regional and whole-body lean mass (LM), fat 
mass, fat percentage, areal bone mineral content (BMC), and areal bone mineral density were 
measured. Peripheral quantitative computed tomography (pQCT, XCT-3000, Stratec 
Medizintechnik, Pforzheim, Germany) scans were performed at 4%, 14%, 38% and 66% of tibial 
length, (medial malleolus to medial condyle), distal to proximal, to measure muscle CSA and 
muscle density, tibial mass, tibial CSA and tibial volumetric density across macroscopic (trabecular, 
cortical and total) bone material. Stress-strain index was calculated as primary marker of bone 
strength.29 
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Statistical Analysis 
Data were analyzed using SPSS version 23 (IBM Corp., NY, USA). Variables were assessed 
for normality using the Shapiro-Wilk test. Results for frequency data are presented as 
number/percentage, and mean/standard deviation for normally distributed data, or 
median/interquartile range for non-normally distributed data. Non-normally distributed data were 
analyzed using non-parametric tests. Differences between OCS and controls were measured using 
the Pearson Chi square test, Likelihood Ratio or Fisher's exact test for categorical data, and the 
independent t-tests or Mann-Whitney U tests for continuous variables. One-way analysis of 
variance (ANOVA), Kruskal-Wallis and Bonferroni post hoc tests were used to compare NACT, 
PDS and controls. Association between variables for OCS was determined by Pearson r or 
Spearman rho correlations. All tests were two-tailed, with statistical significance set at an alpha 
level of 0.05.  
RESULTS 
Participant Characteristics 
Between July 2015 and May 2016, 20 OCS and 20 controls were recruited (Figure 1). The 
OCS group was on average 5.3 (range 3-18) months post cancer treatment. All women had 
undergone surgery, with 9 (45%) and 11 (55%) having received NACT or adjuvant chemotherapy, 
respectively. Demographic, health and medical characteristics of participants are presented in Table 
1. Most OCS and controls were overweight or obese and reported one or more comorbidity. 
Compared to controls more OCS experienced shortness of breath (45% vs. 5%, p = 0.003) and 
tingling or numbness in their extremities (45% vs. 0%, p <0.001), had a university degree (50% vs. 
15%, p = 0.033) and were currently not working (20% vs. 0%, p = 0.031).   
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Physical Activity and Sedentary Behavior 
All OCS and controls provided ≥4 days of valid accelerometer data. One accelerometer 
worn by a control participant was faulty, resulting in lost data. There were no differences between 
OCS and controls for mean awake wear time (p = 0.301), or time/day spent in LIPA (p = 0.212) or 
MVPA (p = 0.687) (Table 2). Thirty-five percent (n = 7) of OCS vs. 53% (n = 10) of controls 
accrued a total MVPA time consistent with PA recommendations of ≥150 minutes/week. When 
considering MVPA time in ≥10-minute bouts, 20% (n = 4) of OCS vs. 10.5% (n = 2) of controls 
undertook ≥150 minutes/week. 
Mean sedentary hours/day were similar for OCS and controls (p = 0.957). However, 
compared to controls, OCS spent significantly more hours/day (3.1±1.3 vs. 2.4±0.7 h, p = 0.039) 
and a significantly higher percentage of awake wear time/day (21.1±9.4 vs. 15.7±4.7%, p = 0.028) 
in prolonged sedentary bouts.  
Compared to controls, there were no significant differences in average time/day spent in 
LIPA, MVPA or SB for NACT and PDS. However, NACT spent a significantly larger percentage 
of awake wear time/day in prolonged sedentary bouts compared to controls (23.8±12.1 vs. 
15.7±4.7%, p = 0.032, Bonferroni p = 0.028). 
Physical function and muscle strength  
The OCS group had a statistically non-significant slower median 400-meter walk time than 
controls [256.5 (235.0-280.2) vs. 240.4 (225.4-254.6) sec, p = 0.091; Table 3]. The exclusion of an 
extreme outlier (i.e., >3.0 x IQR) from the control group resulted in 400-meter walk time being 
significantly slower for OCS vs. controls [256.5 (235.0-280.2) vs. 239.4 (224.6-251.9) sec, p = 
0.041].  Compared to controls, OCS had significantly lower absolute (21.0±6.8 vs. 26.8±9.6 kg, p = 
0.044) and relative (0.29±0.09 vs. 0.38±0.13 kg/kg body weight, p = 0.023) upper body muscle 
strength. No significant differences were observed between groups for repeated chair rise, 6-m walk 
tests, handgrip strength and lower body muscle strength.  
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There were no significant differences between controls, NACT and PDS for functional or 
strength outcomes. No adverse events were reported regarding any objective measures of physical 
function and muscle strength.  
Body composition and muscle morphology 
Fat mass, LM, muscle CSA and muscle density were not significantly different between 
OCS and controls (Table 4). Compared to controls, OCS had significantly higher areal BMC 
(2262.3±305.1 vs. 2074.9±221.4 g, p = 0.047) and volumetric trabecular density (232.5±44.4 vs. 
207.2±33.1 mg/cm³, p = 0.048). 
There were no significant differences between either treatment group or controls in BMI, fat 
mass, LM, muscle CSA or muscle density. However, compared to PDS, NACT had significantly 
higher appendicular LM (18.9±3.8 vs. 15.9±2.3 kg, p = 0.045, Bonferroni p = 0.047; Figure 2) and 
appendicular LM/height² (6.87±0.89 vs. 5.98±0.54 kg/m², p = 0.026, Bonferroni p = 0.045). 
 
 
Figure 3. Whole body and regional fat and lean mass of NACT, PDS and Control groups 
                *Statistical significance (p < 0.05), CI bars = 95% 
p= 0.513 p= 0.045* p= 0.110 p= 0.342 
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Associations of Activity Behavior with Objective Measures of Physical Function, Body 
Composition and Muscle Morphology.  
Total LIPA time/day (ρ = -0.481, p = 0.032), total MVPA time/day (ρ = -0.737, p < 0.001) 
and total MVPA time/day in ≥10-minute bouts (ρ = -0.702, p = 0.001) were significantly inversely 
correlated with 400-meter walk time.  Only total MVPA time/day in ≥10-minute bouts was 
significantly correlated with repeated chair rise time (ρ = -0.519, p = 0.019). Total MVPA time/day 
in ≥10 minute bouts correlated with muscle CSA (ρ = 0.473, p = 0.035) and muscle density (ρ = 
0.438, p = 0.053). Total sedentary time/day (r = -0.713, p < 0.001), total prolonged sedentary 
time/day (r = -0.449, p = 0.047), and number of prolonged sedentary bouts/day (r = -0.494, p = 
0.027) were significantly inversely correlated with volumetric bone mineral density. Neither PA nor 
sedentary time correlated with age or body composition in this sample of OCS. 
DISCUSSION 
There were five main findings from our cross sectional analysis: compared to controls, OCS: 
(1) spent significantly more time/day in prolonged sedentary bouts; (2) had significantly lower 
cardiorespiratory fitness and upper body strength; (3) had significantly higher areal BMC and 
volumetric trabecular density; (4) had significant differences between treatment groups in 
appendicular LM and appendicular LM/height², but were not significantly different in BMI, LM, fat 
mass, and muscle morphology; and (5) for OCS, MVPA was associated with cardiorespiratory 
fitness, lower extremity function and muscle CSA. Our findings suggest that OCS who engage in 
more MVPA may experience benefits in terms of cardiorespiratory fitness, physical function and 
muscle morphology. 
In this study, OCS did not differ significantly from controls in time spent in LIPA, MVPA 
and sedentary behavior. They did, however, spend significantly more time/day in prolonged 
sedentary bouts. This is consistent with research in breast and lung cancer survivors.24, 30 Despite 
similarities in PA participation between OCS and controls, our findings confirm that most OCS are 
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insufficiently active, with only 20% meeting current PA guidelines for cancer survivors. In addition 
to low PA levels, OCS were sedentary for a large percentage of awake time (66.8±7.6%), of which 
3.1 hours was spent in prolonged bouts. Higher self-reported PA in cancer survivors is associated 
with increased treatment tolerance, physical fitness and function, mental and physical health, and 
reduced risk of recurrence and cancer-specific mortality in certain cancer groups.31 Regardless of 
PA, sedentary time32 and prolonged sedentary bouts33, 34 are associated with adverse health 
outcomes in adults and reduced quality of life in cancer survivors.14, 35 Promotion of regular PA and 
breaking up of sedentary time in post-treatment OCS should be priorities in survivorship care. 
We found that, compared to controls, OCS had significantly lower cardiorespiratory fitness 
and upper body strength, but were similar in other aspects of physical function. Poor 
cardiorespiratory fitness is associated with an increased risk of all-cause and cancer mortality.36, 37 
Impaired cardiorespiratory fitness in OCS has been observed in previous research.38 Impaired 
muscle strength negatively affects functional independence and quality of life, while impaired upper 
body strength can have a debilitating effect on activities of daily living such as lifting, carrying, and 
doing housework.39 The lack of significant differences in gait speed, balance and lower body and 
handgrip strength was unexpected and needs confirmation. Exercise oncology interventions to 
increase cardiorespiratory fitness and upper body strength in OCS are necessary and may help to 
increase survival37 and preserve physical function and quality of life39 in this population. 
Our results show that OCS were comparable to controls in terms of BMI, body weight, fat 
and LM, and muscle morphology, but had significantly higher mean areal BMC and trabecular 
density. The similarities in fat mass and muscle quantity and quality, and higher BMC and 
trabecular density in OCS were unexpected. Many survivors in certain cancer groups experience 
detrimental body composition changes (i.e., increase in fat mass, loss of muscle and/or bone mass) 
due to the combined impact of cancer, treatment and reduced PA.40 Furthermore, previous OC 
research reports low muscle mass and muscle density in 29-50% and 35% of women, respectively, 
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at OC diagnosis41, 42 and bone loss in the first year after OC diagnosis.43 Future longitudinal studies 
are warranted to assess body composition changes through the OC trajectory.   
The differences observed between treatment groups in the current sample are notable. The 
NACT group, but not PDS, spent a significantly larger percentage of awake wear time in prolonged 
sedentary bouts compared to controls. Treatment groups did not significantly differ in terms of 
physical function or muscle strength, but exhibited body composition differences. Significantly 
higher appendicular LM in NACT did not translate into improved function or muscle strength, 
possibly due to their non-significantly higher fat mass (34.0±8.3 vs. 26.4±8.8 kg, p = 0.110). 
Parallels in physical function and strength might also be explained by similarities in muscle quality, 
confirming the previously established association between muscle quality, and physical function 
and muscle strength.44, 45 It is possible that the NACT and PDS groups may have had significantly 
different physiological profiles pre-treatment and that our findings are due to selection bias. The 
observed differences between treatment groups are novel and require further investigation in large 
prospective studies. If confirmed, different exercise intervention strategies may be required based 
on treatment regimen. 
Our study indicates a positive relationship between all intensities of objective PA in OCS 
and cardiorespiratory fitness, while MVPA in ≥10-minute bouts positively correlated with lower 
extremity function and muscle CSA. This finding implies that any PA is better than none, but 
highlights the additional advantages of higher intensity, prolonged PA bouts. The moderate 
correlation between MVPA and muscle morphology requires further investigation, but is notable in 
light of research suggesting an association between low muscle mass46 and density42, 47 at diagnosis 
and mortality in OCS. All sedentary outcome measures were negatively correlated with volumetric 
bone mineral density, confirming the importance of minimizing SB to maintain good bone health in 
OCS. 
This study has important strengths and limitations that should be considered. To our 
knowledge, it is the first study to provide a comprehensive cross-sectional analysis of objectively 
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measured activity behavior, physical function and body composition in post-treatment OCS. Our 
sample of OCS is relatively homogenous in terms of disease and treatment stage. A further strength 
of the study is the inclusion of an age-matched control group. However, the small sample size limits 
interpretation, as the study was underpowered to detect small, but potentially meaningful 
differences between groups. Women with a greater interest in PA may have enrolled in the study 
resulting in potential selection bias. Lastly, due to the study’s cross-sectional design, no inferences 
can be made about changes over time, or causality. Longitudinal studies are needed to objectively 
assess changes in OCS’ activity behaviors and physiological status and to investigate the 
relationship between, and the impact of these changes over time. Physiological differences between 
NACT and PDS also require further investigation.  
CONCLUSION 
In this cross-sectional study, OCS spent more time in prolonged sedentary bouts, had lower 
cardiorespiratory fitness and upper body strength, and higher areal BMC and volumetric trabecular 
density compared to age-matched controls. Women treated with NACT had higher appendicular 
LM compared to those treated with PDS, suggesting that different exercise intervention approaches 
could be required depending on treatment regimen.  In OCS MVPA was associated with 
cardiorespiratory fitness, lower extremity function and muscle cross-sectional area, and sedentary 
behavior was consistently negatively correlated with bone mineral density.  Collectively, our 
findings support the need for future studies in OCS, testing the efficacy of exercise medicine 
interventions to increase MVPA, reduce SB, and improve cardiorespiratory fitness and muscular 
strength.  
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Table 1. Demographic, medical and health characteristics of Cancer and Control groups 
 Cancer group 
(n = 20) 
Control group 
(n = 20) p-value 
Age 63.2±8.9 63.0±9.1 0.944 
Relationship status n % n % 0.490 
Partnered 15 75 13 65 
Not partnered 5 25 7 35 
Educational attainment 0.033* 
Completed secondary school 3 15 9 45 
Post-secondary certificate/diploma 7 35 8 40 
University degree 10 50 3 15 
Employment status 0.031* 
Currently working 7 35 12 60 
Currently not working 4 20 0 0 
Retired 9 45 8 40 
Smoking Status 0.055 
Non smoker 13 65 9 45 
Past smoker 5 25 11 55 
Current smoker 2 10 0 0 
Alcohol drinks per week 0.791 
None 8 40 7 35 
1-7 units 9 45 11 55 
≥8 units 3 15 2 10 
Body mass index 0.924 
Normal (<25.0 kg/m²) 7 35 8 40 
Overweight (≥25.0-29.9 kg/m²) 7 35 7 35 
Obese (≥30.0 kg/m²) 6 30 5 25 
Number of comorbidities 0.426 
None 5 25 4 20 
One 8 40 5 25 
≥Two 7 35 11 55 
Current symptoms/side-effects 
Shortness of breath  9 45 1 5 0.003* 
Tingling, numbness, loss of feeling§ 9 45 0 0 <0.001* 
Swelling of feet and ankles 8 40 6 30 0.507 
Pains or cramps in legs 10 50 8 40 0.525 
Chest discomfort 2 10 2 10 1.000 
§Cancer group n = 18 due to missing data         
*Statistical significance (p < 0.05) 
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Table 2. Accelerometer-assessed sedentary time and physical activity in Cancer, Control, NACT and PDS treatment groups 
Cancer group Control group p-value NACT group PDS group p-value 
(n = 20) (n = 19) T-test (n = 9) (n = 11) ANOVA 
Waking wear time, h/day 14.8±1.1 15.2±1.4 0.301 14.7±1.2 14.9±1.1 0.546 
Sedentary behavior (<100 cpm) 
Total time, h/day 9.9±1.1 9.9±1.1 0.957 9.7±1.4 10.0±0.9 0.864 
Time spent in SB (% of awake time) 66.8±7.6 64.7±4.5 0.301 66.5±10.2 67.1±5.2 0.577 
Time in ≥30 min bouts, h/day 3.1±1.3 2.4±0.7 0.039* 3.5±1.7 2.8±1.0 0.052 
Time in ≥30 min SB bouts (% of awake time) 21.1±9.4 15.7±4.7 0.028* 23.8±12.1 18.9±6.2 0.032* 
Number of ≥30 min bouts/day 3.9±1.4 3.1±0.8 0.055 4.2±1.7 3.6±1.1 0.080 
Light physical activity (100 to <1952 cpm) 
Total time, h/day 4.6±1.2 5.0±0.8 0.212 4.6±1.5 4.5±0.8 0.455 
Time spent in light PA (% of awake time) 30.6±6.6 32.6±4.1 0.278 31.1±9.0 30.2±4.2 0.527 
Moderate physical activity (1952-<5275 
cpm) 
Total time, min/day 17.4 (34.4)† 24.7 (22.3)† 0.667‡ 21.7±18.2 24.0±18.4 0.893 
Vigorous physical activity (≥5275 cpm) 
Total time, min/day 0.0 (0.1)† 0.0 (0.0)† 0.687‡ 0.0(0.3)† 0.0 (0.1)† 0.813‡‡ 
MVPA 
Total time, min/day 17.6 (34.5)† 24.7 (26.9)† 0.687‡ 21.8±18.2 24.3±18.8 0.861 
Time in MVPA (% of awake time) 2.6±2.0 2.7±1.5 0.776 2.4±2.0 2.7±2.1 0.906 
Consistent with ≥150 minutes/week [n (%)] 7 (35) 10 (52.6) 0.267 3 (33.33) 4 (36.36) 
Time in ≥10 min bouts, min/day 5.2 (14.7)† 6.1 (8.7)† 0.835‡ 3.1 (16.5)† 5.6 (16.4)† 0.791‡ 
Consistent with ≥150 minutes/week [n (%)] 4 (20) 2 (10.5) 0.661†† 2 (22.2) 2 (18.2) 0.693 
Time in ≥10 min MVPA bouts (% of awake 
time) 0.6 (1.6)† 0.7 (0.9)† 0.857‡ 0.4 (1.7)† 0.6 (1.7)† 0.804‡ 
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Number of ≥10 min bouts/day 0.3 (0.6)† 0.3 (0.4)† 0.647‡ 0.3 (0.8)† 0.3 (0.7)† 0.778‡ 
NACT = neoadjuvant chemotherapy; PDS = primary debulking surgery; cpm = counts per minute on the vertical axis of hip-worn Actigraph 
accelerometer; SB = sedentary bouts; PA = physical activity; MVPA = moderate-and-vigorous physical activity. 
Values are presented as mean±SD unless otherwise specified 
†Median (interquar le range), ‡Mann-Whitney test, ††Fisher's Exact  
 *Statistical significance (p < 0.05) 
**NACT spent a significantly larger % of awake wear time/day in prolonged sedentary bouts compared to Control group (Bonferroni p = 0.028) 
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Table 3. Physical function and muscle strength values for Cancer, Control, NACT and PDS treatment groups 
Cancer group Control group p-value NACT group PDS group p-value 
(n = 20) (n = 20) T-test (n = 9) (n = 11) ANOVA 
Physical function 
400-meter walk (s) 256.5 (45.2)† 240.4 (29.3)† 0.091‡ 256.7 (22.8)† 244.0 (54.1)† 0.141‡‡ 
400-meter walk (s)¶ 256.5 (45.2)† 239.4 (27.4)† 0.041‡* 256.7 (22.8)† 244.0 (54.1)† 0.072 
Repeated chair rise (s) 12.0 (2.8)† 11.0 (4.0)† 0.242‡ 11.8 (4.0)† 12.1 (3.0)† 0.418‡‡ 
Repeated chair rise (s)¶¶ 11.8 (2.2)† 11.0 (4.0)† 0.351‡ 11.8 (4.0)† 11.9 (2.1)† 0.614‡‡ 
6-meter walk usual pace (s) 4.2±0.5 4.2±0.7 0.817 4.1±0.4 4.2±0.6 0.918 
6-meter walk fast pace (s) 3.2 (0.4)† 3.1 (0.4)† 0.277‡ 3.2 (0.4)† 3.1 (0.5)† 0.544‡‡ 
6-meter walk fast pace (s)¶ 3.2 (0.4)† 3.1 (0.3)† 0.158‡ 3.2 (0.4)† 3.1 (0.5)† 0.362 
6-meter backwards walk (s) 21.0±5.7 19.7±4.2 0.408 20.9±4.5 21.1±6.7 0.711 
Muscle strength 
Absolute strength 
Chest press 1RM (kg)§ 21.0±6.8 26.8±9.6  0.044* 23.3±7.4 18.8±5.7 0.070 
Single leg extension 1RM (kg)§§ 24.1±9.1  25.2±8.4  0.724 26.9±9.4 21.4±8.4 0.384 
Hand grip strength, (kg)§§§ 24.4±6.6 26.8±7.0 0.273 25.2±6.9 23.8±6.7 0.500 
Relative strength 
Chest press§ 0.29±0.09 0.38±0.13 0.023* 0.29±0.60 0.29±0.12 0.078 
Single leg extension§§ 0.33±0.10 0.36±0.12 0.342 0.33±0.07 0.32±0.13 0.640 
Hand grip strength§§§ 0.33±0.08 0.38±0.09 0.112 0.31±0.05 0.35±0.10 0.156 
  
NACT = neoadjuvant chemotherapy; PDS = primary debulking surgery; 1RM = one repetition maximum.     
Values are presented as mean±SD unless otherwise specified 
¶Extreme outlier removed from Control group, ¶¶Extreme outlier removed from Cancer group 
†Median (interquar le range), ‡Mann-Whitney test, ‡‡Kruskal-Wallis test 
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Relative strength was calculated by dividing absolute strength by body weight  
§Cancer group n = 18, Control group n = 19, PDS group n = 9 due to inability complete upper body strength measures 
§§Cancer group n = 18, Control group n = 18, PDS group n = 9 due to inability complete lower body strength measures 
 §§§Control group n = 19 due to inability complete hand grip strength measures 
*Statistical significance (p < 0.05) 
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Table 4. Body composition and muscle density values for Cancer, Control, NACT and PDS treatment groups 
Cancer group Control group p-value NACT group PDS group p-value 
(n = 20) (n = 20) T-test (n = 9) (n = 11) ANOVA 
BMI 27.4±4.5 27.2±4.5 0.888 29.57±3.90 25.64±4.25 0.139 
Height (cm) 163.9±7.1 162.9±9.4 0.657 165.3±6.5 162.7±7.8 0.630 
Waist to hip ratio 0.84 (0.7)† 0.84 (0.10)† 0.947‡ 0.84 (0.05)† 0.84 (0.09)† 0.798‡‡ 
DXA 
Body weight (kg) 74.2±15.4 72.2±10.6 0.632 81.1±14.7 68.5±14.1 0.086 
Whole body fat mass (kg) 29.8±9.2 28.0±7.9 0.500 34.0±8.3 26.4±8.8 0.110 
Trunk fat mass (kg) 13.5±5.0 12.5±4.6 0.520 15.0±3.8 12.2±5.6 0.342 
Whole body fat percentage (%) 39.4±5.3 38.1±6.6 0.491 41.6±4.7 37.6±5.4 0.264 
Whole body LM (kg) 42.0 (8.5)† 40.8 (8.0)† 0.862‡ 44.7±7.5 40.0±5.6 0.513‡‡ 
Appendicular LM (kg) 17.3±3.4 17.7±2.2 0.610 18.9±3.8 15.9±2.3 0.045** 
Appendicular LM/height² 
(kg/m²) 6.4±0.8 6.7±0.8 0.256 6.9±0.9 6.0±0.5 0.026** 
Whole-body aBMC (g)§ 2262.3±305.1 2074.9±221.4 0.047* 2393.0±267.7 2157.7±304.6 0.025*** 
Whole-body aBMD (g/cm²)§ 1.08±0.10 1.05±0.08 0.263 1.11±0.10 1.06±0.10 0.257 
pQCT 
Muscle area (mm²) 5862.5±1184.4 6088.4±708.1 0.469 6312.1±1455.4 5494.6±800.0 0.131 
Muscle density (mg/cm³) 72.4 (5.8)† 74.2 (3.9)† 0.221‡ 72.8 (4.1)† 72.0 (7.3)† 0.423‡‡ 
Tibial mass g/cm 3.0±0.5 2.8±0.3 0.940 3.2±0.5 2.9±0.4 0.062 
Tibial area (mm²) 665.0±92.5 632.5±64.6 0.205 675.6±103.4 656.4±86.7 0.394 
Tibial vBMD (mg/cm³) 555.9±72.5 532.5±53.3 0.252 579.4±73.2 536.6±69.2 0.170 
Trabecular area (mm²) 491.8±70.5 464.3±53.8 0.173 495.42=±76.0 488.9±69.4 0.390 
Trabecular vBMD (mg/cm³) 232.6±44.4 207.3±33.2 0.048* 252.9±42.7 216.0±40.2 0.015*** 
Cortical area (mm²) 218.6±32.7 212.7±23.1 0.514 228.9±33.7 210.1±30.8 0.273 
52 
 
Cortical vBMD (mg/cm³) 1110.9±47.7 1101.4±33.6 0.469 1124.2±46.2 1100.0±48.3 0.331 
SSI (mm³) 1511.7 (287.9)† 1468.6 (244.5)† 0.369‡ 1654.3±332.7 1437.2±208.7 0.063 
NACT = neoadjuvant chemotherapy, PDS = primary debulking surgery, BMI = body mass index, FM = fat mass, LM = lean mass,    
aBMC = areal bone mineral content, aBMD = areal bone mineral density, vBMD = volumetric bone mineral density, SSI = stress-strain index. 
Values are presented as mean±SD unless otherwise specified 
†Median (interquar le range), ‡Mann-Whitney test, ‡‡Kruskal-Wallis test 
 §Cancer group n = 18, Control group n = 17, NACT Group n = 8, PDS Group n = 10 due to metallic surgical implants 
*Statistical significance (p < 0.05) 
**Appendicular LM (kg) and appendicular LM/height² (kg/m²) was significantly higher in NACT than PDS, Bonferroni p = 0.047 and 0.045, respectively 
***BMC (g) and trabecular density (mg/cm³) was significantly higher in NACT than in Control group, Bonferroni p = 0.021 and 0.013, respectively 
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ABSTRACT  
Purpose: Little is known about the relationship between health-related quality of life (HRQoL), 
pelvic floor dysfunction (PFD) and modifiable lifestyle and physiological factors for ovarian cancer 
survivors (OCS). This study aimed to compare post-treatment advanced-stage OCS with age-
matched controls on measures of HRQoL and PFD. Associations between HRQoL, PFD, objective 
activity behaviors, physical function and body composition in OCS were also examined. 
Methods: Twenty advanced-stage OCS and 20 controls completed questionnaires assessing 
HRQoL (SF-36) and PFD (Australian Pelvic Floor Questionnaire), and underwent objective 
assessments of activity behavior (7-day accelerometry), physical function (400-meter walk, 
repeated chair rise, 6-meter usual-pace walk, 1-repetition maximum chest press and single leg 
extension) and body composition (dual-energy x-ray absorptiometry).  
Results: Compared to controls, OCS had worse physical HRQoL (-4.3 median difference, p= 
0.013), but equivalent self-reported PFD, indicated by combined bladder, bowel and pelvic organ 
prolapse symptoms (0.89 mean difference, p= 0.277). In OCS physical HRQoL was significantly 
negatively associated with PFD (r= 0.468, p= 0.043). Decreased physical HRQoL and increased 
PFD were significantly associated with less moderate-and-vigorous physical activity in ≥ 10-minute 
bouts (ρ= 0.627, p= 0.003; ρ= -0.457, p= 0.049), more sedentary time (r= -0.449, p= 0.047; r= 
0.479, p= 0.038) and slower 400-meter walk time (ρ= -0.565, p= 0.022; ρ= 0.504, p= 0.028). 
Conclusions: Post-treatment advanced-stage OCS have decreased physical HRQoL, which is 
associated with modifiable factors such as PFD, moderate-and-vigorous physical activity, sedentary 
time and objective physical function. This highlights the need for ongoing supportive care and 
multidisciplinary interventions after first-line OC treatment. 
Key Words: Ovarian cancer, Health-related quality of life, Pelvic floor dysfunction, Moderate-and-
vigorous physical activity (MVPA), Sedentary time  
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INTRODUCTION 
Ovarian cancer (OC) is the seventh most common cancer among women worldwide.1 
Between 70% and 75% of OC cases are diagnosed at an advanced stage.2 Treatment in advanced-
stage OC is often palliative and aimed at controlling disease and treatment related symptoms and 
side-effects, whilst prolonging survival with optimal quality of life.3 As such, health-related quality 
of life (HRQoL) in women with OC has received increasing attention in the last decade.4  
Although research involving measurement of HRQoL in ovarian cancer survivors (OCS) is 
increasing, interpretation of results can be challenging due to heterogeneity of study design and 
participant groups (e.g., different disease stages and  treatments). Furthermore, existing studies 
mostly investigate HRQoL in long-term OCS (≥ five years post-diagnosis) or in women on 
treatment, with little information for OCS following first-line treatment.5 Few studies have 
compared HRQoL between OCS and age-matched controls drawn from the same community.6, 7 
Health-related QoL in OCS is known to be negatively impacted by persistent treatment-
related side-effects.4 Poorer HRQoL has been linked with lifestyle factors such as obesity and 
insufficient self-reported physical activity (i.e., <150 minutes of moderate-and-vigorous physical 
activity [MVPA] per week).8, 9 However, associations of HRQoL with body composition and 
objectively measured activity behaviors (i.e., physical activity [PA] and sedentary behavior [SB]) 
have not yet been examined.  Furthermore, although most QoL instruments measure self-rated 
physical function, the relationship between objectively measured physical function and HRQoL in 
OCS has not been explored previously.  
Pelvic floor dysfunction (PFD) is widely recognized as a public health issue with significant 
impact on HRQoL for millions of women globally.10, 11 Although gynecological cancer treatment is 
often considered a risk factor for increased PFD, this association has not been firmly established.12 
Pelvic floor dysfunction is a general term that refers to clinical problems involving different organ 
systems in the same anatomical area. It encompasses symptoms associated with bladder, bowel and 
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pelvic organ prolapse (POP), and sexual dysfunction.13 Sexual dysfunction and gastrointestinal 
issues such as constipation, diarrhea and indigestion after OC treatment are well documented,14, 15 
but data regarding the prevalence, severity and impact of PFD in OCS are limited.16  
To design and implement tailored interventions aimed at improving HRQoL for OCS, it is 
crucial to understand the relationship between HRQoL and modifiable factors such as PFD, activity 
behaviors, physical function and body composition. We have previously reported that, compared to 
age-matched controls, OCS spent significantly more time/day in prolonged sedentary bouts of ≥30 
minutes and had significantly lower cardiorespiratory fitness and upper body strength.17 In this 
report we extend our previous analysis to: (1) compare HRQoL and PFD in OCS who had 
completed first-line treatment to age-matched controls; (2) investigate associations between HRQoL 
and PFD in OCS; and (3) explore associations of HRQoL and PFD with objective activity 
behaviors, physical function and body composition in OCS.  
METHODS  
Setting and participants 
The study was conducted at the Exercise Medicine Research Institute at Edith Cowan 
University and St John of God Subiaco Hospital in Perth, Western Australia. The Human Research 
Ethics Committees of both institutions granted ethical approval (Ref. No. 12511, 23/4/2015; Ref. 
No. 815, 12/6/2015).  Ovarian cancer survivors were eligible for participation if they had 
histologically confirmed stage III–IV epithelial OC, were 3-24 months post completion of first-line 
treatment, were ≥18 years of age, received approval from the treating oncologist or general 
practitioner, were able to walk 400 meters, were proficient in English, had no existing or suspected 
bone metastases, no acute illness or any musculoskeletal, cardiovascular or neurological disorder 
that could put them at risk during exercise testing. The same non-cancer eligibility criteria applied 
for controls. All participants provided written informed consent. 
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Outcome Measures 
Demographic, medical, HRQoL and pelvic floor data were obtained by self-report 
questionnaires. Additional information regarding cancer diagnosis and treatment were collected 
from OCS. All anthropometric measures (height and body weight to calculate body mass index 
[BMI], waist and hip circumference to calculate waist-to-hip ratio), body composition and objective 
functional data were collected at the Exercise Medicine Research Institute by one investigator (CS).  
Health-related Quality of Life 
Health-related QoL was measured using the Medical Outcomes Study Short Form-36 (MOS 
SF-36) questionnaire.18 The SF-36 is a generic instrument that comprises eight subscales measuring 
Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, 
Role-Emotional and Mental Health. Subscale scores were combined into a physical component 
summary score (PCS) and a mental component summary score (MCS).19 All scores were 
standardized to 1998 general US population norms.20 Higher scores reflect better HRQoL in the 
domain being measured.20 The SF-36 has been established as a reliable and valid measure of QoL21 
and is often used to assess QoL of OCS.4 
Pelvic Floor Dysfunction 
Self-reported PFD was measured with the Australian Pelvic Floor Questionnaire (APFQ).22, 
23 The APFQ has four subscales, with a range of questions each, to assess bladder, bowel and POP 
symptoms, and sexual function.  Bladder, bowel and POP symptom scores out of 10 were 
calculated. We did not calculate sexual function scores due to the large percentage of women (55% 
of all participants) indicating sexual inactivity and thus not completing the section. Bladder, bowel 
and POP symptom scores out of 10 were added for a combined bladder-bowel-POP symptom score 
out of 30, hereafter referred to as the Pelvic Floor Score. Higher scores in all domains indicate that 
women are experiencing more symptoms and thus more dysfunction. The APFQ has been indicated 
as valid and reliable measure of all four pelvic floor domains.22, 23 
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Physical Activity and Sedentary Behavior 
Objective PA and sedentary time were measured over a seven-day period with a hip-worn 
tri-axial accelerometer (ActiGraph GT3X+, ActiGraph Corp, FL, USA). Data processing details 
have been reported previously.17 Activity counts were categorized as: sedentary (<100 
counts/minute [cpm]), light intensity PA (100-<1952 cpm), moderate intensity PA (1952-<5275 
cpm), vigorous intensity PA (≥5275 cpm), or MVPA (≥1952 cpm).24, 25 Moderate-and-vigorous PA 
was assessed as total MVPA time/day and MVPA time/day in strict ‘bouts’ of ten consecutive 
minutes or more with no interruption.   
Physical Function and Muscle Strength 
Objective measures of physical function included: (1) 400-meter walk as an indicator of 
cardiorespiratory fitness,26 (2) repeated chair rise to measure lower extremity function,27 (3) 6-meter 
usual pace walk to measure gait speed during daily activities, (4) 6-meter backwards walk to 
measure dynamic balance.28, 29 All tests, except for the 400-meter walk test, were performed in 
triplicate and the fastest of each was used for analysis. Upper and lower body muscle strength was 
measured with one repetition maximum (1-RM) chest press and single leg extension (dominant leg 
unless contraindicated), respectively. Relative strength was calculated by dividing absolute strength 
by body weight. 
Body Composition and Muscle Morphology 
Body composition was measured by dual-energy x-ray absorptiometry (DXA, QDR-1500, 
Hologic Discovery A, Waltham, MA). Participants’ regional and whole-body lean mass, fat mass, 
fat percentage, areal bone mineral content and areal bone mineral density were measured. 
Peripheral quantitative computed tomography (pQCT, XCT-3000, Stratec Medizintechnik, 
Pforzheim, Germany) scans were performed to measure muscle cross-sectional area and density, 
and tibial mass, cross-sectional area and volumetric density across macroscopic (trabecular, cortical 
and total) bone material.  
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Statistical Analysis 
Data were analyzed using SPSS version 23 (IBM Corp., NY, USA). The Shapiro-Wilk test 
was used to assess normality of variables. Results for frequency data are presented as 
number/percentage, and mean/standard deviation for normally distributed data, or 
median/interquartile range for non-normally distributed data. Non-parametric tests were used to 
analyze non-normally distributed data. Probability of significant differences between OCS and 
controls were determined using the Pearson Chi square test, Likelihood Ratio or Fisher's exact test 
for categorical data, and independent t-tests or Mann-Whitney U tests for continuous variables. 
Pearson r or Spearman rho correlations were used to determine association between variables for 
OCS. All tests were two-tailed, with statistical significance set at an alpha level of 0.05. 
RESULTS 
Participant recruitment details and characteristics have been reported previously.17 Briefly, 
20 OCS and 20 controls were recruited between July 2015 and May 2016. Eligible OCS were 
recruited via the consulting rooms of three gynecologic oncologists. Controls were recruited via 
snowball sampling, from staff at a local university and hospital, and from the wider community. 
The OCS-group was on average 5.3 months (range 3-18) post cancer treatment. All OCS had 
undergone surgery, with 9 (45%) and 11 (55%) having received neoadjuvant or adjuvant 
chemotherapy, respectively. There were no differences between OCS and controls for age (63.2±8.9 
vs. 63.0±9.1 years; p = 0.944) or BMI (27.4±4.5 vs. 27.2±4.5 kg/m²; p = 0.888). Most OCS and 
controls reported one or more comorbidities (75% vs. 80%; p = 0.426). More OCS than controls 
had obtained a university degree (50% vs. 15%; p = 0.033), while more controls than OCS were 
currently working (100% vs. 80%; p = 0.031).    
Health-related Quality of Life and Pelvic Floor Dysfunction 
Compared to controls, OCS had significantly lower scores in three of the four physical 
component subscales, namely Physical Functioning (p = 0.024), Role Physical (p = 0.023) and 
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General Health (p = 0.021), as well as PCS (p = 0.013). No statistical differences were observed 
between OCS and controls for any of the mental component subscales, or MCS (Figure 4).  
An extreme outlier (i.e., >3.0 x IQR) was removed from the control group for the Pelvic 
Floor Score. No significant differences were observed between OCS and controls for Bladder, 
Bowel or POP Scores, or the Pelvic Floor Score. Seventy percent (n = 14) of OCS vs. 40% (n = 8) 
of controls were sexually inactive (chi square = 3.636; p = 0.057) (Table 5). 
Associations between Health-related Quality of Life and Pelvic Floor Dysfunction in 
Ovarian Cancer Survivors  
Bladder Score was significantly inversely correlated with Physical Functioning (ρ = -0.451; 
p = 0.046), Role Physical (r = -0.533; p = 0.016), General Health (r = -0.475; p = 0.034) and PCS (r 
= -0.520; p = 0.019). Bowel Score was significantly inversely correlated with Physical Functioning 
(ρ = -0.478; p = 0.039), Role Physical (r = -0.479; p = 0.038), General Health (r = -0.571; p = 
0.011), Vitality (r = -0.554; p = 0.014), Role Emotional (ρ = -0.490; p = 0.033), Mental Health (r = -
0.499; p = 0.030) and PCS (r = -0.473; p = 0.041). Pelvic Floor Score was significantly inversely 
correlated with Physical Functioning (ρ = -0.509; p = 0.026), Role Physical (r = -0.482; p = 0.036), 
General Health (r = -0.558; p = 0.013), Role Emotional (ρ = -0.509; p = 0.026) and PCS (r = -0.468; 
p = 0.043). 
Associations between Health-related Quality of Life and Activity Behavior, Physical 
Function and Body Composition in Ovarian Cancer Survivors 
We have previously conducted a comprehensive cross-sectional assessment of objectively 
measured activity behavior and physical function, and body composition in OCS, compared to age-
matched controls. Results are reported elsewhere.17 
In this study MVPA time/day was significantly correlated with Physical Functioning (ρ = 
0.532; p = 0.016), Bodily Pain (ρ = 0.521; p = 0.018), General Health (ρ = 0.511; p = 0.021), and 
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PCS (ρ = 0.606; p = 0.005). Moderate-and-vigorous PA time/day in ≥ 10-minute bouts was 
significantly correlated with Physical Functioning (ρ = 0.499; p = 0.025), Bodily Pain (ρ = 0.531; p 
= 0.016) and PCS (ρ = 0.627; p = 0.003). Sedentary time/day was significantly inversely correlated 
with Physical Functioning (ρ = -0.578; p = 0.008), Role Physical (r = -0.454; p = 0.045), General 
Health (r = -0.720; p = <0.001), Vitality (r = -0.656; p = 0.002), Mental Health (r = -0.636; p = 
0.003) and PCS (r = -0.449; p = 0.047).  
Six-meter usual walk time was significantly inversely correlated with Physical Functioning 
(ρ = -0.655; p = 0.002) and PCS (r = -0.588; p = 0.006). Four hundred meter walk time was 
significantly inversely correlated with Physical Functioning (ρ = -0.608; p = 0.004), Bodily Pain (ρ 
= -0.514; p = 0.020) and PCS (ρ = -0.565; p = 0.009) Relative lower body strength was significantly 
correlated with PCS (r = 0.537; p = 0.022).  
Neither BMI nor any of the body composition components were correlated with any of the 
HRQoL domains. 
Associations between Pelvic Floor Dysfunction, and Activity Behavior, Physical 
Function and Body Composition in Ovarian Cancer Survivors 
Moderate-and-vigorous PA time/day in ≥ 10-minute bouts, but not total MVPA time/day, 
was significantly inversely correlated with Pelvic Floor Score (ρ = -0.457; p = 0.049). Sedentary 
time/day was significantly correlated with Bowel Score (r = 0.531; p = 0.019) and Pelvic Floor 
Score (r = 0.479; p = 0.038).  
Six-meter usual walk time was significantly correlated with Bladder (r = 0.729; p = <0.001) 
and Pelvic Floor Scores (r = 0.514; p = 0.024). Four hundred meter walk time was significantly 
correlated with Bladder (ρ = 0.554; p = 0.011) and Pelvic Floor Scores (ρ = 0.504; p = 0.028). 
Relative upper and lower body strength were significantly inversely correlated with Bladder Score 
(r = -0.477; p = 0.045, r = -0.541; p = 0.020)  
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No significant correlations were observed between BMI or components of body 
composition, and PFD. 
DISCUSSION 
The purpose of this cross-sectional study was to assess HRQoL and PFD in advanced-stage 
OCS, compared to age-matched controls. A secondary objective was to investigate associations 
between HRQoL, PFD, objective activity behaviors and physical function, and body composition in 
OCS. We found that OCS had worse physical HRQoL, but equivalent self-reported PFD compared 
to controls. Ovarian cancer survivors who reported more symptoms related to PFD had lower 
physical HRQoL. Worse physical HRQoL and greater PFD in OCS were associated with less 
MVPA in ≥ 10 minute bouts, more sedentary time and lower levels of objective physical function. 
Physical HRQoL, but not PFD, was positively associated with total MVPA time/day. 
Our sample of OCS reported significantly lower physical and functional, but equivalent 
social, emotional and mental HRQoL compared to age-matched controls from the same community. 
Our findings are not consistent with a recent study which reported that stages I-IV OCS one year 
post-diagnosis have comparable HRQoL to the general US female population.5  This may be due to 
the inclusion of women with early-stage disease who may have had better physical function5 
compared to only advanced-stage OCS in our study. We found no research that investigated 
HRQoL in advanced-stage OCS early after completion of first-line treatment. Studies comparing 
HRQoL of OCS and controls drawn from the same community have included stage I-IV OCS more 
than five years since diagnosis, with mixed results.30, 31 Our findings suggest that advanced-stage 
OCS following first-line treatment experience physical health and functional limitations that 
negatively impact their daily living. Although this finding needs to be substantiated in larger 
studies, it highlights the need for ongoing care to address physical and functional limitations after 
completion of first-line OC treatment.  
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To our knowledge, this is the first study to examine the relationships between HRQoL, 
objectively measured activity behaviors and physical function, and body composition in OCS. 
Health-related QoL in OCS has previously been associated with symptom burden, self-reported PA 
and obesity.4, 8 We found that better physical HRQoL was also associated with more MVPA, less 
sedentary time and better objective physical function in OCS. An association between HRQoL and 
MVPA, but not sedentary time, has been previously shown in colon cancer survivors.32 Our data 
suggests that interventions aimed at increasing MVPA, reducing sedentary time and improving 
physical function could improve HRQoL for OCS. 
 Advanced-stage OCS in this study reported equivalent levels of PFD, as indicated by bladder, 
bowel and POP symptoms, but 30% higher rates of sexual inactivity, compared to controls. 
Research in gynecological cancer survivors indicates that rates of urinary incontinence and other 
pelvic floor symptoms are high even before commencement of cancer treatment; however, the 
prevalence of symptoms does not differ compared to non-cancer controls.12, 33 Studies investigating 
PFD after completion of gynecological cancer treatment suggest that, compared to controls, 
gynecological cancer survivors have equivalent urinary incontinence and POP, but more fecal 
incontinence and sexual inactivity.6, 7 One reason for the difference between our observation and 
findings in gynecological cancer survivors regarding bowel symptoms could be related to different 
treatment regimens. Radiation therapy is not used in first-line OC treatment, but is common in 
endometrial and cervical cancer treatment,34 and is associated with detrimental radiation-induced 
gastrointestinal toxicities.35 Although clearly OCS may experience severe and debilitating PFD, our 
data suggest that the prevalence of self-reported PFD is not different in advanced-stage OCS 
compared to similarly-aged women with comparable BMI in the general population.  
It is notable that OCS who experienced more PFD also reported worse HRQoL, consistent 
with research in the general population of women.10, 11 Existing evidence indicates that some 
aspects of PFD are treatable, for example, pelvic floor muscle training has been shown to be 
effective in treating urinary incontinence.36 Evidence-based education and screening of OCS for 
68 
 
PFD at diagnosis and throughout their cancer journey is required, with appropriate referral for 
assessment and treatment when indicated. The level of PFD experienced by individual OCS should 
guide recommendations and precautions for physical activity participation, exercise testing and 
exercise training. 
In the general female population, pelvic floor dysfunction is associated with modifiable risk 
factors such as low self-reported PA levels,37 reduced physical function38 and obesity.39 We found 
that OCS with more PFD spent less time/day doing MVPA in ≥ 10-minute bouts. This is consistent 
with results from a recent study indicating an inverse association between MVPA in ≥ 10-minute 
bouts and PFD in middle-aged women from the general population.40 These findings suggest that 
the prevalence of PFD may not affect participation in light, informal PA associated with daily 
living, but negatively affects participation in planned, purposeful and repetitive MVPA (i.e., 
exercise) in ≥ 10-minute bouts, which is associated with optimal health benefits.41 In our study OCS 
with more PFD also accrued more sedentary time/day and had worse objective physical function. 
Future research is needed to determine to what extent increased PFD in OCS affects physical 
activity participation and sedentary behavior, and subsequently objective physical function. Best 
current evidence suggests that most PA does not harm the pelvic floor; however, more research is 
needed to fill existing knowledge gaps.37 For OCS with multiple pelvic floor symptoms, 
multidisciplinary interventions aimed at treating PFD while incorporating exercise training could be 
beneficial. Conversely, findings from our study suggest that many OCS who have completed first-
line treatment experience only a few mild pelvic floor symptoms (e.g., 58% of OCS scored ≤5/30 
for combined bladder, bowel and POP symptoms). Physical activity and exercise participation for 
these OCS should not be restricted based on pelvic floor concerns, especially considering potential 
improvements in cancer survivors’ HRQoL after participating in exercise programs.42  
Notably, in this study HRQoL and PFD in OCS were not associated with BMI or 
components of body composition (e.g., lean mass, fat mass or fat percentage). This was a surprising 
finding considering that existing evidence supports associations between obesity and decreased 
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HRQoL in OCS8 and between obesity and PFD in the general population.39, 43 These findings may 
be due to our study being underpowered to detect such associations and require further investigation 
in larger prospective studies. 
Limitations of the study include the cross-sectional study design, which does not allow 
inferences to be made regarding changes over time or causality. As we did not adjust data for 
multiple comparisons, three of our findings could be due to chance.  The small sample size limits 
generalization of results. An objective measurement of PFD (e.g., ultrasound) and/or the inclusion 
of questions regarding previous treatments and known risk factors (e.g., parity and vaginal birth) for 
PFD would have provided a better understanding of PFD in both OCS and controls. We 
acknowledge the possibility of recruitment bias, as women with severe pelvic floor symptoms might 
not have volunteered for participation due to their perceived inability to complete functional tests. 
Our study provides important preliminary information about associations between HRQoL and 
objectively measured activity behaviors and physical function, and body composition in OCS. 
Furthermore, this is the first study to provide a comprehensive cross-sectional analysis of self-
reported PFD and its associations with HRQoL, objectively measured activity behavior, physical 
function and body composition in OCS. Further strengths of our study include the relative 
homogeneity of our sample of OCS in terms of disease and treatment stage and the inclusion of an 
age-matched control group from the same community.   
CONCLUSION  
In this cross-sectional study advanced-stage OCS who had completed first-line treatment 
had lower physical, but equivalent mental HRQoL, compared to controls. Ovarian cancer survivors 
who reported better physical HRQoL did more MVPA/day, spent less time/day sedentary and had 
better objective physical function. Pelvic floor dysfunction was not significantly different between 
OCS and controls. Ovarian cancer survivors with more PFD had worse physical and mental 
HRQoL, did less MVPA in ≥10-minute bouts, spent more time/day sedentary and had worse 
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objective physical function. Post-treatment advanced-stage OCS have decreased physical HRQoL, 
which is associated with modifiable factors such as PFD, MVPA, sedentary time and objective 
physical function. This highlights the need for ongoing supportive care and the importance of 
multidisciplinary interventions beyond the completion of first-line OC treatment. 
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Figure 4. Median SF-36 subscale scores for Cancer and Control groups 
                *Statistical significance (p < 0.05) 
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Table 5. Bladder, bowel and pelvic organ prolapse symptoms scores for Cancer and Control groups 
  Cancer group  Control group  p-value 
  (n = 20) Median (Range) (n = 20) Median (Range) T-test 
Bladder score (/10) 1.11 (1.89)† 1.11 (0.00-4.00) 1.33 (1.61)† 1.33 (0.22-5.11) 0.989‡ 
Bowel score (/10)§ 2.23±1.87 2.06 (0.00-6.18) 1.97±1.38 2.06 (0.00-4.41) 0.626 
POP score (/10)§§ 0.00 (0.00)† 0.00 (0.00-2.00) 0.00 (0.00)† 0.00 (0.00-4.67) 0.901‡ 
Pelvic Floor Score (/30) 4.05 (4.85)† 4.06 (0.00-8.71) 3.03 (2.66)† 3.03 (0.52-13.90) 0.624‡ 
Pelvic Floor Score (/30)¶ 4.17±2.94 4.06 (0.00-8.71) 3.28±1.86 3.03 (0.52-7.83) 0.277 
Sexually active n (%) n (%) 0.057† 
Yes 6 (30) 12 (60) 
No 14 (70) 8 (40) 
POP = Pelvic organ prolapse; Pelvic Floor Score = combined bladder, bowel and POP symptoms score for each participant  
†Pearson Chi-square 
Values are presented as mean±SD unless otherwise specified 
†Median (interquar le range), ‡Mann-Whitney test 
§Cancer group n = 19, §§Control group n = 19 due to missing data 
¶Extreme outlier removed from Control group 
*Statistical significance (p < 0.05) 
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Chapter 5 
CONCLUSION 
 
OVERVIEW 
This research aimed to provide a comprehensive profile of activity behaviors and 
physiological characteristics of advanced-stage OCS who have completed first-line treatment. This 
chapter is a summary of findings from the literature review (Chapter Two) and observational study 
(Chapters Three and Four), while highlighting the strengths, challenges and clinical implications of 
this work.  
Chapter Two provides a summary of current literature relating to treatment-related side-
effects, concurrent comorbidities, body weight and composition, physical fitness and function, and 
PA behavior of OCS. Findings from the literature review indicate that women diagnosed with OC 
are faced with many challenges, such as persistent disease and treatment symptoms and side-effects, 
concurrent comorbidities, obesity and physical inactivity. Overall, current literature is limited by a 
lack of objectively measured data and the heterogeneous nature of existing OC studies. 
Therefore, the primary aim of the observational study was to extend current literature by 
assessing objectively measured activity behaviors (i.e., PA and sedentary behavior) and physical 
function, body composition and musculoskeletal morphology of post-treatment advanced-stage 
OCS compared to age-matched controls. Self-reported PFD and HRQoL of this sample of OCS 
were also assessed. The results were that, compared to age-matched controls, OCS spent more time 
in prolonged sedentary bouts, had lower cardiorespiratory fitness, upper body strength and physical 
HRQoL, but had equivalent self-reported PFD. Further, better physical HRQoL was associated with 
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more time spent doing MVPA, less time spent in sedentary behavior, better objective physical 
function and less PFD. These findings suggest that many of the issues associated with reduced 
physical HRQoL in post-treatment advanced-stage OCS are potentially modifiable with a 
multidisciplinary approach that includes exercise oncology interventions. 
LIMITATIONS, STRENGTHS AND IMPLICATIONS FOR 
PRACTICE 
The study design and modest sample size limit conclusions that can be drawn from this work. 
Despite these limitations, the thesis provides important preliminary information about objectively 
measured activity behaviors and physical function, body composition, musculoskeletal morphology, 
self-reported PFD and HRQoL in post-treatment advanced-stage OCS. Conducting the 
observational study provided challenges and insights worth considering in the development of 
exercise intervention studies and exercise oncology guidelines.  
Recruitment of participants for clinical research is known to be challenging and time-
consuming. In the current study there were several factors that impacted eligibility and recruitment.  
A large percentage of OCS (20%) identified by clinicians as potentially eligible for the study could 
not be reached, despite various attempts to contact them.  Another 20% had recurrent disease at the 
time of recruitment, or were too unwell to participate. A portion of eligible OCS (27%) declined the 
invitation to participate due to lack of interest. Research in cancer populations indicates that clinical 
trials are often considered an inconvenience to everyday life.1 Additionally, several eligible OCS 
(14%) expressed interest to participate, but declined based on the fact that they lived far from the 
location where assessments were conducted. This is consistent with previous research reporting 
transportation issues and distance to trial sites as patient-related barriers to participation.1 Similar 
challenges are likely to present when recruiting participants for exercise intervention studies and 
need to be considered when developing strategies for recruitment of OCS into exercise intervention 
studies.  
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In the observational study, no adverse events were reported as result of functional and 
strength testing. However, one repetition maximum (1-RM) strength testing was contra-indicated in 
a small percentage of OCS (10% for 1-RM chest press, 10% for with 1-RM single leg extension) 
with joint replacements or severe arthritis. In designing the study, a single leg extension 1-RM test 
was selected as a conservative measure considering the possible high prevalence of PFD after OC 
treatment. Based on our findings regarding the prevalence of PFD in OCS, a more functional 
measure of lower body strength, such as the leg press, may be considered for OCS without 
musculoskeletal and/or PFD contraindications. This work suggests that the majority of OCS can 
safely undergo functional and strength testing, but that certain tests should be modified following 
screening for comorbid conditions, PFD and treatment side-effects. This is likely to hold true for 
exercise interventions, which may require an individualized approach based on participants’ 
treatment side-effects (e.g., peripheral neuropathy), comorbidities (e.g., arthritis, osteoporosis) and 
current level of physical fitness and function. As such, comprehensive screening for the prevalence 
and severity of persistent treatment side-effects and comorbidities, and exercise testing to determine 
physical fitness and function, should precede exercise interventions. 
This was the first study to assess PFD in OCS. However, only self-reported PFD was 
assessed. Some objective measurement of PFD (e.g., ultrasound), as well as the inclusion of 
questions regarding previous treatments for PFD and known risk factors for PFD (e.g., parity and 
vaginal birth) would have provided a more complete picture of PFD for both OCS and controls. 
This research suggests that OCS should undergo PFD screening to identify pelvic floor symptoms 
that could necessitate an individualized approach to exercise testing and prescription. 
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FUTURE RESEARCH 
This thesis describes the activity behaviors, objective physiological characteristics, HRQoL 
and self-reported PFD of post-treatment advanced-stage OCS. However, possible differences that 
were not extensively investigated in our current study may exist based on the type of OC, treatment 
stage and/or treatment regime. In this research study, differences were observed regarding some 
activity behaviors and physiological characteristics based on type of treatment previously received. 
This suggests that OCS on different treatment regimens may require different exercise intervention 
strategies. Longitudinal studies incorporating larger sample sizes are needed to investigate potential 
activity behavior and physiological differences between “sub-groups” of advanced-stage OCS (e.g., 
women with different types of OC and on different treatment regimens). Changes in activity 
behavior, physiological characteristics and HRQoL of advanced-stage OCS over the entire disease 
spectrum also need to be investigated. Furthermore, findings of this thesis suggest that the physical 
HRQoL of post-treatment advanced-stage OCS are affected by potentially modifiable factors such 
as insufficient MVPA and reduced objective physical function. Future pilot studies and randomized 
controlled trials are needed to assess the feasibility and efficacy of tailored exercise interventions in 
advanced-stage OCS who have completed first-line treatment. 
CONCLUSION 
In conclusion, this research examined activity behaviors and physiological characteristics of 
post-treatment advanced-stage OCS to inform the design of supportive care interventions. Overall, 
the findings of this research are that advanced-stage OCS who have completed first-line treatment 
are insufficiently physically active and have decreased physical HRQoL, which is associated with 
modifiable factors such as MVPA, sedentary time, objective physical function and PFD. Post-
treatment OCS require ongoing multidisciplinary supportive care delivered by a team of allied 
health professionals that includes exercise physiologists. Future exercise intervention studies are 
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required to investigate the feasibility and benefits of exercise as medicine for women who have 
completed first-line treatment for advanced-stage OC. 
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Appendix A – Detailed methods section 
SETTING AND PARTICIPANTS 
 The study was conducted at the Exercise Medicine Research Institute at Edith Cowan 
University and St John of God Subiaco Hospital in Perth, Western Australia. Ethical approval was 
granted by the Edith Cowan University (Ref. No. 12511, 23/4/2015; Appendix B) and St John of 
God Health Care Human Research Ethics Committees (Ref. No. 815, 12/6/2015; Appendix C). Two 
groups of women were recruited: (1) ovarian cancer survivors (OCS) (n = 20) and (2) similarly 
aged women with no previous cancer diagnosis (n = 20). We required 22 participants for each group 
in order to achieve 80% statistical power at an alpha level of 0.05 (two-tailed) to detect a difference 
in leg strength between groups. The power calculation was based on a publication in which a mean 
difference in leg strength (1-RM leg press) of 22.5 kg, and a pooled variance of 25.5 kg (effect size 
= 0.88) were reported between women with breast cancer and similarly aged women with no history 
of cancer.1 Due to recruitment of OCS being slower than expected, we only managed to recruit 20 
women in the allotted time frame. 
Ovarian cancer survivors were eligible for participation if they had histologically confirmed 
stage III – IV epithelial OC and were between 3 and 24 months post cancer-related treatment 
(surgery and chemotherapy), were 18 years or older, able to obtain approval from their treating 
oncologist or general practitioner, able to walk 400 meters, able to understand and speak English, 
and had no existing or suspected bone metastasis, no acute illness or any musculoskeletal, 
cardiovascular or neurological disorder that could put them at risk during exercise testing. The same 
non-cancer eligibility criteria applied for the control group. Written informed consent was obtained 
from all participants. 
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DESIGN AND RECRUITMENT  
We conducted a cross-sectional study. Participants for the OC group were recruited by 
screening for potentially eligible participants in the rooms of three gynecological oncologists in 
Perth. Potentially eligible OCS were informed of the research study either via a phone call from the 
practice nurse or an information letter (Appendix D) and study brochure (Appendix E) sent out 
from the oncologists’ rooms. The study coordinator (CS) then contacted potentially eligible 
participants by phone to determine interest and confirm eligibility.  
Participants for the control group were recruited by several methods. Initially participants 
from the cancer group were asked if they had similarly aged female family members or friends who 
would be willing to participate in the study. When required, control participants were recruited from 
staff at the Edith Cowan University and a local cancer care center (Appendix F), and the wider 
community. Interested women were asked to contact the study coordinator to confirm eligibility. 
Women were recruited as control participants if they could be age-matched to an OC participant, 
i.e., if they were of similar age, or no more than two years older or younger. 
A study information pack containing a cover letter (Appendix G), participant  information 
letter (Appendix H and I), medical consent form (Appendix J and K),  participant consent form 
(Appendix L), demographic and health history questionnaire (Appendix M) and a Day 1 letter 
(Appendix N) was posted to all interested and eligible participants. Follow-up telephone calls were 
made one week after posting the study information packs to confirm receipt, answer questions 
regarding the study and book assessments.   
STUDY PROCEDURES 
All participants underwent two separate assessments, no less than six, but no more than 14 
days apart. Assessments took 2.5-3.0 hours and 1.5-2.0 hours respectively to complete and were 
conducted at the Edith Cowan University Exercise Medicine Research Institute. All anthropometric, 
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body composition and objective functional data were collected by the study coordinator, an 
accredited exercise physiologist. 
On commencement of the first assessment, consent forms, demographic and medical history 
questionnaires, and study procedures were reviewed with participants. Participants were also 
provided an opportunity to ask questions regarding the study. Anthropometric measures and resting 
heart rate and blood pressure measures were completed. In addition, each participant underwent a 
dual-energy X-ray absorptiometry (DXA) body composition and peripheral quantitative computed 
tomography (pQCT) scan, and completed a series of functional measures for familiarization 
purposes. At the end of the assessment, participants were provided with an ActiGraph (GT3X+) 
accelerometer, an instruction sheet for accelerometer use (Appendix O), an activity monitor log 
(Appendix P) and a second questionnaire assessing health-related quality of life (HRQoL), pelvic 
floor dysfunction (PFD), physical activity (PA) level and PA motivation (Appendix Q).   
To minimize the learning effect, all functional tests were repeated during the second 
assessment. After completion of all tests on the second day, the study coordinator provided 
feedback and exercise advice to interested participants.  
OUTCOME MEASURES 
Demographic and medical data were obtained by self-reported questionnaires and provided 
information regarding participants’ age, marital status, educational attainment, employment status 
and medical history. Additional information regarding date of cancer diagnosis, date of treatment 
completion, cancer stage and treatment(s) received were acquired from OCS.  
Anthropometric measures  
Height (m) and body weight (kg), measured by digital measuring-and-weighing station 
(Model 763, Seca, Hamburg, Germany), were used to calculate body mass index (BMI) in m/kg². 
Waist and hip circumference (cm) were measured at the narrowest part of the torso or between the 
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iliac crest and 12th rib, and the maximal circumference of the hip.2 Waist-to-hip ratio was 
calculated by dividing waist circumference by hip circumference. For accurate set-up of the pQCT 
scanner, left tibial length (with one exception due to a metal implant) was measured in cm from the 
tibial plateau at the knee joint (proximal end) to the medial malleolus of the tibia (distal end). All 
measures were recorded to the nearest 0.1. 
Body composition 
Whole-body DXA scans were performed using DXA (QDR-1500, Hologic Discovery A, 
Waltham, MA, USA) to measure participants’ regional and whole-body lean and fat mass, as well 
as bone mineral content (g) and areal bone mineral density (g/cm²). Dual-energy X-ray 
absorptiometry has been established as a valid3, 4 and reliable5  measure of body composition and 
has often been used to assess body composition or components thereof in a variety of cancer 
populations.6-9 
In addition to DXA scans, tibial peripheral quantitative computed tomography (pQCT) scans 
(pQCT, XCT-3000; Stratec Medizintechnik, Pforzheim, Germany) were conducted. In contrast to 
DXA, pQCT differentiates between trabecular and cortical bone and provides volumetric bone 
mineral density values (in mg/cm³) of bone tissue at peripheral skeletal sites, thus providing more 
comprehensive bone tissue information.10 Furthermore, while DXA measures fat and muscle mass, 
pQCT provides information on the quality of muscle due to the ability to generate estimations of 
muscle density.11 Four pQCT scan slices were measured at 4%, 14%, 38% and 66% of tibial length 
respectively (distal to proximal). Variables across all tibial slices were retained for analysis. 
Trabecular density and trabecular area were obtained from the 4% slice, cortical density and cortical 
area were averaged across the 14% and 38% tibial slices, muscle density and muscle area were 
obtained from the 66% slice, and tibial mass, total tibial area and tibial density were averaged 
across the 4%, 14%, and 38% tibial slices. 
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Physical activity and sedentary time  
Objective PA and sedentary time were measured with a hip-worn tri-axial accelerometer 
(ActiGraph GT3X+, ActiGraph Corp, FL, USA). Participants were asked to wear the accelerometer 
continuously for seven days, except when bathing/showering or participating in water-based 
activities. The GT3X+ was programmed to record raw data at a frequency of 30Hz, which were 
later reduced to vertical axis movement counts/60 s epoch for the purpose of our analyses. 
Accelerometer data were downloaded with Actilife (Version 6.13.3, ActiGraph Corp, FL, USA) and 
processed in SAS (Version 9.3, SAS Institute Inc., NC, USA). An automated algorithm was used to 
identify awake wear time12 and non-wear time.13 Non-wear time is defined as 90-minute periods of 
zero acceleration counts/minute [cpm], with allowance for 2-min intervals of non-zero counts for 
detection of accidental movement of the monitor, e.g., touching of monitor sitting on a table or 
nightstand).13 To render days of data collection valid, a minimum awake wear time of 600 minutes 
(10 hours) was required.14 A minimum of four valid days was required for analysis. Activity counts 
were categorized as: sedentary (<100 cpm), light intensity PA (LIPA; 100-<1952 cpm), moderate 
intensity PA (1952-<5275 cpm), vigorous intensity PA (≥5275 cpm), or moderate-to-vigorous PA 
(MVPA; ≥1952 cpm).15, 16 Moderate-to-vigorous PA was assessed as total MVPA time/day and 
MVPA time/day in strict ‘bouts’ of ten consecutive minutes or more with no interruption. 
Participants were categorized as meeting (i.e., ≥150 minutes of MVPA/week) or not meeting (i.e., 
<150 minutes of MVPA/week) current PA guidelines for cancer survivors.17 Prolonged sedentary 
bouts were defined as uninterrupted sedentary bouts of ≥30 minutes. Accelerometers are 
increasingly being used to measure time spent, and patterns of accumulation, in different intensities 
of physical activity and sedentary behavior.18-20  
Self-reported physical activity was assessed by the Leisure Score Index (LSI) of the Godin 
Leisure Time Exercise Questionnaire (GLTEQ). The questionnaire asks participants to recall their 
average weekly frequency and duration of mild, moderate and strenuous activity during the past 
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month. The GLTEQ is considered a valid and reliable measure of self-reported physical activity21 
and is often utilized to assess physical activity behavior in gynecological cancer survivors.22, 23 
Objective physical function 
Objective physical function was assessed through a battery of tests including: (1) a series of 
6-meter walking tasks, (2) 400-meter walking test, (3) repeated chair rise, and (4) muscular strength 
tests. The study coordinator gave demonstrations of the 6-meter backwards walk, repeated chair rise 
and strength tests and allowed sufficient rest periods between different tests as well as between 
trials within a specific test. Participants were reminded that they could discontinue any test that 
caused excessive discomfort or pain. 
6-Meter walk tests – Three separate tests were conducted: (1) a usual pace walking test to 
assess gait speed during daily activities, (2) a fast pace walking test to assess the fastest self-
selected pace participants could safely walk at, and (3) a backwards walking test to assess dynamic 
balance.23, 24 A 6-meter distance was marked with tape on the floor. Participants were instructed to 
start walking from the 0-meter mark when ready and to continue walking past the 6-meter mark to 
eliminate the effect of deceleration. For the backwards walk, participants were instructed to walk in 
reverse on the 6-meter line following a toe-to-heel protocol. If participants lost balance and deviated 
from the line, they were instructed to return to the line and continue walking. Time taken to 
complete each task was measured by electronic timing gates (Swift Performance Equipment, NSW, 
Australia) and the fastest of three trials for each 6-meter walking test was used for analysis. Both 
the 6-meter walk test and the 6-meter backwards walk have been reported to have good test-retest 
reliability.25-27 
400-Meter walk test - Participants walked 400 meters by doing 10 laps of a 20-meter 
course, marked with cones on the floor, in a long corridor. They were instructed to start on the 
command “GO” after a “three-two-one” countdown, and to walk at the fastest pace they could 
maintain over the total distance. Time taken to complete the 400-meter walk was measured by 
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handheld stopwatch. The 400-meter walk test was developed as a practical alternative to maximal 
or submaximal treadmill testing, to measure cardiorespiratory fitness in older adults.28 The test has 
been reported as a valid measure of cardiorespiratory fitness28, 29 and mobility,30 with excellent test-
retest reliability (ICC = 0.95).29 
Repeated chair rise – Participants were seated in a hard-backed chair (chair height = 46cm) 
with their backs against the backrest and arms folded across their chests. They were instructed to 
stand up to a fully upright position (knees fully extended) and to sit back down with upper backs 
touching the back rest, as fast as they could safely do so five times. As with the 400-meter walk test, 
participants were instructed to start on the command “GO” after a “three-two-one” countdown, and 
time taken to complete the task was measured by handheld stopwatch. The fastest of three trials was 
used for analysis. The repeated chair rise has been reported as a valid test for lower extremity 
function31 with good test-retest reliability.25, 32 
Muscular strength – One repetition maximum (1-RM) chest press and single leg extension 
tests were used to measure dynamic upper and lower body muscular strength respectively. In 
addition, isometric handgrip strength, reported to be a valid indicator of limb muscle strength,33 was 
measured in all participants. All absolute strength values were divided by body weight to provide 
information on relative strength. 
One-RM testing is considered the “gold standard” of muscular strength testing34 and refers 
to the maximal weight (in kg) an individual can move once with good technique through full range 
of motion without compensatory movements. The 1-RM chest press was conducted on a Cybex 
Smith machine (Cybex International, Medway, MA, USA) and a portable flat bench. The bar was 
positioned at mid-sternal level and 90° elbow flexion for each participant. Lifts were only recorded 
as successful if executed to full elbow extension. The 1-RM single leg extension was conducted on 
a Cybex leg extension machine. The back rest and shin pad were adjusted after each participant was 
seated to ensure that the knee joint was in line with the machine pivot point and at a 90° angle, and 
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that the shin pad was positioned just above the ankle joint. Only movements executed to the same 
degree of knee extension as during the warm-up were recorded as successful. Participants received 
demonstrations and instructions concerning correct posture, breathing and movement execution 
during both the familiarization and the follow-up sessions of 1-RM testing.  
The 6-meter walking tasks, 400-meter walk and repeated chair rise were all conducted prior 
to strength testing and served as general warm-up for 1-RM tests. Participants performed two 
warm-up set of six and three repetitions respectively for each movement (chest press, right leg 
extension and left leg extension, unless contraindicated). Subsequent attempts required single 
movement executions at progressively heavier loads until the absolute 1-RM was determined. Rest 
intervals between warm-up sets and 1-RM trials were two minutes. A maximal of three to five 1-
RM trials were attempted to avoid the effect of fatigue. One-RM testing, with  one familiarization 
session 4-8 days prior, has been reported to be a safe and reliable method of maximal strength 
testing in older, untrained participants34 and has been utilized to measure muscular strength in a 
variety of cancer populations.35-37  
To measure handgrip strength participants were asked to stand upright whilst holding a 
Jamar handgrip dynamometer (Lafayette, IN, USA) in their right hand, arm slightly away from the 
body with approximately 20° elbow flexion, and to squeeze the dynamometer handle as forcefully 
as possible. After a score was recorded, the test was repeated with the left hand. Three trials were 
done for each hand, right and left alternatively, with a 30-second rest between each set of trials. The 
highest score for the right hand was used for analysis. Good inter-tester38 and test-retest reliability39 
has been established for handgrip dynamometry and, due to ease of application, the test is often 
used for objective strength assessment in clinical populations, including different cancer 
populations.40, 41   
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Health-related Quality of Life 
Health-related quality of life was measured using the Medical Outcomes Study Short Form-
36 (MOS SF-36) questionnaire.42 The SF-36 is a generic instrument that comprises eight subscales 
measuring Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social 
Functioning, Role-Emotional and Mental Health. Subscale scores were combined into a physical 
component summary score (PCS) and a mental component summary score (MCS).43 All scores 
were standardized to 1998 general US population norms so each scale is scored to have the same 
average (50) and the same standard deviation (10). Higher scores reflect better HRQoL in the 
domain being measured.44 The SF-36 has been established as a reliable and valid measure of quality 
of life45 and is often used to assess quality of life of OCS.46 
Pelvic Floor Dysfunction 
Self-reported PFD was measured with the Australian Pelvic Floor Questionnaire (APFQ).47, 
48 The APFQ has four subscales, with a range of questions each, to assess bladder, bowel and pelvic 
organ prolapse (POP) symptoms and sexual function.  Bladder, bowel and POP symptom scores out 
of 10 were calculated. We did not calculate sexual function scores due to the large percentage of 
women (55% of all participants) indicating sexual inactivity and thus not completing the section. 
Bladder, bowel and POP symptom scores out of 10 were added for a combined bladder-bowel-POP 
symptom score out of 30. Higher scores in all domains indicate that women are experiencing more 
symptoms and thus more dysfunction. The APFQ has been indicated as valid and reliable measure 
of all four pelvic floor domains.47, 48  
STATISTICAL ANALYSIS 
Data were analyzed using SPSS version 23 (IBM Corp., NY, USA). Variables were assessed 
for normality using the Shapiro-Wilk test. Results for frequency data are presented as 
number/percentage, and mean/standard deviation for normally distributed data, or 
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median/interquartile range for non-normally distributed data. Non-normally distributed data were 
analyzed using non-parametric tests. Probability of significant differences between OCS and control 
participants were measured using the Pearson Chi square test, Likelihood Ratio or Fisher's exact test 
for categorical data, and the independent t-tests or Mann-Whitney U tests for continuous variables. 
One-way analysis of variance (ANOVA), Kruskal-Wallis and Bonferroni post hoc tests were used 
to compare OCS treated with primary debulking surgery and adjuvant chemotherapy, OCS treated 
with neoadjuvant chemotherapy and interval debulking surgery and control participants. 
Association between variables for OCS was determined by Pearson r or Spearman rho correlations. 
All tests were two-tailed, with statistical significance set at an alpha level of 0.05.  
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        Date 
           
Dear Mrs…….. 
Exercise needs in ovarian cancer survivors 
The St John of God Gynaecologic Oncology research group is collaborating with 
researchers at Edith Cowan University in a study which I would like to invite you to take 
part in. The aim of this research study is to determine what types of exercise would be 
most appropriate for women who have recently completed treatment for ovarian cancer.  
Please find a brochure enclosed that provides further information about the research. Your 
participation is entirely voluntary and you are not under any obligation to be involved. 
Christelle Schofield, the chief study investigator, will contact you by telephone to see if you 
are interested in being involved and to answer any questions that you may have.  
Your participation in this would be most appreciated as it will help to improve our 
understanding of cancers and treatments and thus to improve care for our patients. 
 
 
Yours sincerely 
 
 
(Dr’s Name) 
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                 Date 
 
Mrs……….. 
8  Any Street, 
Suburb,  
WA, 2122 
 
Dear Mrs…….. 
 
Thank you for your interest in the research study, Physiological and disease specific 
characteristics of ovarian cancer survivors.  
 
Please find enclosed: 
1. A participant information letter outlining all aspects of the study 
2. A medical doctor consent form for your GP or specialist 
3. An informed consent form for you  
4. A demographic and health history questionnaire  
5. Details of your first appointment 
6. A parking permit for the Vario Clinic/Health and Wellness Institute parking area 
 
Please read the participant information letter carefully. If you decide to participate 
in the study: 
1. Take the MEDICAL DOCTOR CONSENT FORM to your GP/specialist. 
2. Following approval from your doctor to participate, please contact me to 
arrange a meeting where an orientation to the study will be provided and 
baseline measurements will commence. 
3. Bring the medical doctor consent form, signed by your GP, with you on your first 
assessment appointment. Everything else you will need on the first 
appointment is outlined in the DAY 1 – ASSESSMENT sheet included in the 
package. 
4. I will contact you in a few days to confirm that you have received the 
documents. However, if you have any questions in the meantime, please do not 
hesitate to contact Christelle Schofield on 0459 900 264 or via e-mail at 
c.schofield@ecu.edu.au.  
 
Yours sincerely 
 
 
 
Christelle Schofield  
Accredited Exercise Physiologist 
Masters Student – Edith Cowan University Health and Wellness Institute 
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INFORMATION LETTER TO PARTICIPANTS – CANCER SURVIVORS 
Physiological and disease specific characteristics of 
ovarian cancer survivors 
 
You are invited to participate in a research study because you have had a diagnosis of ovarian cancer. 
This information letter explains the purpose and nature of the study and describes what will be 
involved should you decide to participate. Please read the sheet carefully and do not hesitate to 
contact the chief investigator if anything requires further clarification or if you have additional 
questions or concerns. Please ensure that you do this before you sign the consent form to participate 
in the study. 
 
Contact persons 
 
If you have any questions about the study, you can contact: 
Mrs Christelle Schofield (Chief Investigator) - 0459 900 264 
Prof Robert Newton (Principle Supervisor) - 08 6304 3443 
 
Decision to participate 
  
Your decision to participate in this study is voluntary. No explanation or justification is needed if you 
choose not to participate. If you do decide to participate, you are free to withdraw your consent and 
discontinue your involvement at any time during the study. A decision not to participate will not 
disadvantage you or jeopardise your relationship with your care provider in any way. You will be 
given a copy of the Consent Form to keep for your personal record. 
 
The Participant Information Sheet explains the study and includes details such as: 
o why this study might be suitable for you 
o possible benefits and risks of study participation 
o the type, frequency and risks of any testing that you will need to have as part of this study 
o what your rights and responsibilities are if you agree to participate 
 
What is the purpose of the study? 
 
Women with ovarian cancer often experience a significant burden of disease and treatment side-
effects. Exercise has been acknowledged as a safe and effective supportive care intervention for 
cancer survivors. Currently it is unknown what exercise is most appropriate for addressing the 
disease specific and functional needs of women with ovarian cancer. The purpose of the study is to 
measure physical function (i.e. walking speed, balance, muscle strength), body composition (i.e.  
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how much muscle you have, your bone mineral density), physical activity participation and pelvic 
floor function in ovarian cancer survivors. We plan to look at how these results relate to results 
of similarly aged women who have not had cancer to better understand the specific exercise 
needs of ovarian cancer survivors. Information obtained from this research will assist health 
professionals to make exercise recommendations and to design the most appropriate exercise 
programs for ovarian cancer survivors.    
  
 
Am I eligible for participation? 
 
As an ovarian cancer survivor to participate in the study you need to 
 Be 18 years or older 
 Have histologically confirmed stage III – IV ovarian cancer 
 Not have cancer that has spread to the bone 
 Not have undergone cancer-related surgery, chemotherapy and/or radiation therapy during  
the last 3 months 
 Not have completed your cancer-related treatment more than 24 months ago 
 Not have an acute illness at the time of testing  
 Not have any musculoskeletal, cardiovascular or neurological disorder that could put you at 
risk during exercise testing, as determined by your specialist or general practitioner 
 
What does participation in the study involve? 
 
If you agree to participate in the study, you will be asked to 
 Obtain consent from your specialist or general practitioner 
 Invite a female friend, colleague or relative of similar age as yourself, who has never had a 
diagnosis of cancer, to participate in the control group of this study. You are under no 
obligation to do this, but if you know someone who would be willing and interested to 
participate in the study, you can   
o ask her to contact the chief investigator directly AND/OR 
o give her the INFORMATION LETTER TO PARTICIPANTS – CONTROL GROUP included in your 
package 
 Complete standardized questionnaires  
 Undergo a series of assessments at the Edith Cowan University in Joondalup to measure 
different components of your physical fitness. 
 
What questionnaires do I have to complete? 
 
You will be asked to complete standardized questionnaires used to record demographic and 
health history information as well as to assess quality of life, pelvic floor function, physical 
activity level, physical activity motivation, and your thoughts on participating in the study. The 
questionnaires can be completed in the privacy of your own home and are anticipated to take 
you approximately half an hour. 
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What do the assessments involve? 
 
As study participant you will undergo the following series of assessments:  
 
 Body Composition & Bone Mineral Density 
o Dual Energy X-Ray Absorptiometry (DEXA) scan will be used to assess whole body 
composition (fat mass and lean mass) and bone mineral density of the hip and spine. 
These assessments involve lying still on a specially designed platform for approximately 
10 minutes while a scanning arm will move above your total body and above your hip and 
spine (separate scans for your whole body, hip and spine). A low-dosage x-ray will pass 
from the scanning arm to underneath the platform.   
o Peripheral Quantitative Computed Tomography (pQCT) will be used to measure muscle 
density and muscle cross-sectional areas of the lower limb. The assessment involves you 
sitting in a chair with your leg extended and the circular scanning arm moving from your 
ankle to your knee.   
 
The total radiation dose for all scans undertaken during the study is very low, only a little more 
than normal background radiation from an airplane flight and much less than, for example, an 
international flight.  
 
 Physical Activity Level 
You will be asked to wear an activity monitor (triaxial accelerometer) 24 hours a day for a 7-
day period in order to accurately measure your physical activity levels (i.e. how long you are 
active for in a day). The device is very small (4.6cm x 3.3cm x 1.5cm), lightweight (19g) and 
can be attached to your belt or worn around your waist using a strap. 
 
  Physical Function 
 A series of tests will be used to assess physical function. Before physical function tests are 
performed, you will receive detailed instructions regarding all tests. Where necessary, 
demonstrations, practice time and sufficient warm-up will be undertaken. All tests will be 
supervised by the chief investigator, an accredited exercise physiologist, and your safety will 
be observed at all times. These tests involve: 
 
o 6-meter walk: You will be asked to walk 6 meters at your usual pace and at a fast pace 
(i.e. as if you were running late for an appointment) (performed 3 times).   
o 6-meter backwards walk: As a test of balance, you will be asked to walk backwards in a 
toe-to-heel fashion for 6 meters (performed 3 times). 
o 400-meter corridor walk: You will be asked to walk 20 meters in a corridor, turn around 
and walk back to the starting position for a total of 10 times. 
o Chair rise: You will be seated in a hard-backed chair and asked to rise and sit 5 
consecutive times, as fast as you can safely do so, without the use of your arms for 
support (performed 3 times). 
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o Muscle strength: You will be asked to perform an upper and lower body one repetition 
maximum test. During the one repetition maximum test you will be asked to lift 
increasingly heavy weights on a chest press and leg extension weight-training machine 
until you reach the most weight you can lift once using correct technique. In addition, 
you will be asked to perform a hand-grip strength test, which entails squeezing a hand 
dynamometer as hard as possible. Adequate rest will be provided in between tests to 
avoid fatigue. 
 
You will be asked to do these assessments on two separate occasions as outlined below, no 
less than 6 but no more than 14 days apart. The purpose of the first testing session is to 
familiarise you with all functional assessments in order to minimise any potential learning 
effect. All testing will be conducted at the Edith Cowan University Health and Wellness 
Institute in Joondalup (see map included) and will take approximately 2-3 hours.  
 
OUTLINE OF TESTING SESSIONS 
Session 1 Session 2 (6-14 days after Session 1) 
The chief investigator will  
 review consent forms, demographic and 
health history questionnaire and study 
procedures with you 
 hand out quality of life, pelvic floor 
function and physical activity 
questionnaires 
 provide you with an activity monitor 
 measure your height and weight 
  
The chief investigator will 
 review quality of life, pelvic floor 
function and physical activity 
questionnaires with you 
 collect the activity monitor from you 
 provide verbal feedback and an 
(optional) exercise counselling to you 
after conducting all tests 
 
You will undergo a DEXA and pQCT scan.  
You will undergo functional testing: 
 6-Meter walk test 
o Usual pace forward 
o Fast pace forward 
o Toe-to-heel backward 
You will undergo functional testing: 
 6-Meter walk test 
o Usual pace forward 
o Fast pace forward 
o Toe-to-heel backward 
 400-Meter walk test  400-Meter walk test 
 Chair raise  Chair raise 
 Muscle strength testing 
o One repetition maximum 
tests 
o Grip strength test 
 
 Muscle strength testing 
o One repetition maximum 
tests 
o Grip strength 
How long will it take? 
 2.5 hours for assessment 
 30 minutes at home to complete 
questionnaires 
 
How long will it take? 
 2 hours for assessment 
 30 minutes for (optional) exercise 
counselling 
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What are the possible benefits of participating? 
 
The direct benefit for you is that all study activities, including all assessments, are provided 
at no cost to you. At the end of the second testing session the chief investigator will provide 
feedback regarding your test results.  You will then be offered the choice of either: 
 No exercise consultation, OR 
 A brief 30-minute exercise consultation with the chief investigator immediately after 
the second testing session, OR 
 A more comprehensive 60-minute exercise consultation with the chief investigator 
on another day at a time agreeable to both parties. 
 
During the consultation of your choice the chief investigator will make exercise 
recommendations based on your test results and answer any exercise related questions you 
may have. Additionally, it is hoped that this study will contribute important new information 
that will be useful in the management of ovarian cancers and long-term treatment side 
effects. 
 
What are the possible side effects and risks?  
 
Prior to any testing, your specialist or GP will review your medical history and the study 
protocols to make sure that it is safe for you to take part in the assessments involved in the 
study. However, any strength and physical functional testing may result in mild discomfort 
and muscle soreness. There is also the possibility of muscle pulls or strains, common to any 
type of physical activity. Risk of falling may exist in the performance of some tasks. In order 
to minimize these risks you will be thoroughly familiarized with the movements involved in 
this investigation through comprehensive instructions and demonstrations, and supervised 
at all times by the chief investigator, an accredited exercise physiologist. Furthermore, 
during exercise testing it is possible to experience symptoms such as abnormal blood 
pressure, fainting, light-headedness, nausea, and in very rare cases heart rhythm 
disturbances or heart attack. These potential risks are common to any form of physical 
activity. You will be asked to report any symptoms you experience during exercise testing 
and your safety will be of primary importance at all times. In the event that an emergency 
occurs, medical assistance will be obtained according to established emergency procedures 
at the ECU Health and Wellness Institute.  
 
DEXA and pQCT scans are routine clinical tests, but carry a small risk to you as they involve 
exposure to radiation. The level of radiation exposure is exceedingly small (10-30 
microSieverts [µSv]) in comparison to the natural annual radiation dose in western 
communities (approximately 3000 µSv).  A person would receive radiation exposure of 
approximately 80 µSv on an airline flight of 8 hours or 30 to 40 µSv during a typical chest x-
ray.  
 
You may experience some discomfort in answering the items in the questionnaires. Your 
responses will be kept strictly confidential. Some of the questions will ask about the level of 
distress you are experiencing. If our study identifies that you are experiencing significant 
distress you will be contacted and your permission will be sought to inform your GP or 
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cancer specialist so that referral to appropriate services can be made. In addition, if you 
should experience and express any distress at any stage during participation in the study, 
the chief investigator will offer you the opportunity to contact a support person of your 
choice (i.e. your husband or a friend). It is also recommended that you obtain permission 
from your GP to be contacted if you feel you would rather contact him/her in case you 
experience significant distress. 
 
Privacy and confidentiality 
 
The conduct of this research involves the collection, access and/or use of your identified 
personal information. The information collected is confidential and will not be disclosed to 
third parties without your consent, except to meet government, legal or other regulatory 
authority requirements. A de-identified copy of this data may be used for other research 
purposes. However, your anonymity will be safeguarded at all times. Participants will not be 
referred to by name in research reports or during study discussions. If the results of the 
study are published in a scientific journal, as is intended, no reader will be able to identify 
individual patients.  All records will be stored in a locked filing cabinet in a private office on 
the Joondalup campus of Edith Cowan University with restricted access for a minimum of 
five years.  All computer records are restricted by password.  
Are there any costs involved? 
 
If you choose to participate in the study, you will be asked to attend two testing sessions at 
ECU in Joondalup.  Parking for visitors is available on campus at a cost of $1.50 per hour. 
The parking permit included in the package will allow you access to the Health and Wellness 
Institute’s parking area close to the building where you will undergo testing (indicated on 
the included campus map). Please note that you still have to pay for parking and that tickets 
can be purchased at vending machines located in the parking area.  To help cover travel and 
parking expenses, you will be provided with a $25.00 voucher at your second testing 
session.  
 
Will I receive any feedback? 
 
You will receive verbal feedback regarding your test results at the end of the second testing 
session. If you would like to discuss your results and ask questions about exercise, you have 
the choice of either a brief 30-minute exercise consultation with the chief investigator 
immediately after the second session or a more comprehensive 60-minute exercise 
consultation on another day at a time agreeable to both parties. During the consultation of 
your choice the chief investigator will make exercise recommendations based on your test 
results and answer your exercise-related questions. A summary of study results will be made 
available to all interested participants upon completion of the study.  
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Contacting the investigators  
 
We are happy to answer any questions you may have at this time. If you have any queries 
later, please do not hesitate to contact either: 
Mrs Christelle Schofield    Phone: 0459 900 264               E-mail: c.schofield@ecu.edu.au 
Prof Robert Newton     Phone: (08) 6304 3443             E-mail: r.newton@ecu.edu.au 
 
Independent Contact Person 
 
The ECU Human Research Ethics Committee and the Human Research Ethics Committee at 
St John of God Hospital, Subiaco have approved this project. If you have any concerns or 
complaints about the research project and wish to talk to an independent person, you may 
contact: 
 
Research Ethics Officer 
Edith Cowan University 
270 Joondalup Drive 
JOONDALUP WA 6027 
Phone: (08) 6304 2170 
Email: research.ethics@ecu.edu.au 
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

-ECU Health & Wellness Institute is located in building 21 on the Joondalup Campus of Edith    
Cowan University.  
-Please come to the Institute entrance located between building 21 and building 19 and 
check in with reception.  
-Parking is available for ECU Health & Wellness Institute clients directly behind building 19.  
-Parking charges are $1.50/hour.  
-If you have any problems locating the parking area please contact Christelle on 0459 900 
264.  
DIRECTIONS FROM THE FREEWAY:  
• Take the Hodges Drive exit  
• Turn Right onto Hodges Drive  
• Turn right onto Joondalup Drive  
• Turn left onto Lakeside Drive  
• Turn left onto Chancellors Pass  
• Turn left at the round-a-bout  
• Take the first right into the Institute Client Car Park (to your right)  
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INFORMATION LETTER TO PARTICIPANTS – CONTROL 
GROUP 
Physiological and disease specific characteristics of 
ovarian cancer survivors 
 
You are invited to participate in a research study because you have expressed an interest to 
participate in the control group of an ovarian cancer study. This information sheet explains 
the purpose and nature of the study and describes what will be involved should you decide 
to participate. Please read the sheet carefully and do not hesitate to contact the chief 
investigator if anything requires further clarification or if you have additional questions or 
concerns. Please ensure that you do this before you sign the consent form to participate in 
the study. 
 
Contact persons 
 
If you have any questions about the study, you can contact: 
Mrs Christelle Schofield (Chief Investigator)  - 0459 900 264 
Prof Robert Newton (Principle Supervisor) - 08 6304 3443 
 
Decision to participate 
  
Your decision to participate in this study is voluntary. No explanation or justification is 
needed if you choose not to participate. If you do decide to participate, you are free to 
withdraw your consent and discontinue your involvement at any time during the study. A 
decision not to participate will not disadvantage you or jeopardise your relationship with 
your care provider in any way. You will be given a copy of the Consent Form to keep for your 
personal record. 
 
The Participant Information Sheet explains the study and includes details such as: 
o why this study might be suitable for you 
o possible benefits and risks of study participation 
o the type, frequency and risks of any testing that you will need to have as part of this 
study 
o what your rights and responsibilities are if you agree to participate 
 
 
Appendix I – Information letter- control 
participants 
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What is the purpose of the study? 
 
Women with ovarian cancer often experience a significant burden of disease and 
treatment side-effects. Exercise has been acknowledged as a safe and effective 
supportive care intervention for cancer survivors. Currently it is unknown what exercise is 
most appropriate for women with ovarian cancer to address their disease specific physical 
functioning needs. The purpose of the study is to measure physical function (i.e. walking 
speed, balance, muscle strength), body composition (i.e. how much muscle you have, 
your bone mineral density), physical activity participation and pelvic floor function in 
ovarian cancer survivors. We plan to look at how these results relate to results of similarly 
aged women who have not had cancer to better understand the specific exercise needs of 
ovarian cancer survivors. Information obtained from this research will assist health 
professionals to make exercise recommendations and to design the most appropriate 
exercise programs for ovarian cancer survivors. 
 
Am I eligible for participation? 
 
To participate in the partner/control group of the study you need to 
 Be 18 years or older 
 Never have had a diagnosis of cancer or history of cancer (other than non-melanoma 
skin cancer) 
 Not have an acute illness at the time of testing 
 Not have any musculoskeletal, cardiovascular or neurological disorder that could put 
you at risk during exercise testing, as determined by your specialist or general 
practitioner 
 
What does participation in the study involve? 
 
If you agree to participate in the study, you will be asked to 
 Obtain consent from your specialist or general practitioner 
 Complete standardized questionnaires  
 Undergo a series of assessments at the Edith Cowan University in Joondalup to 
measure different components of your physical fitness. 
 
What questionnaires do I have to complete? 
 
You will be asked to complete standardized questionnaires used to record demographic 
and health history information as well as to assess quality of life, pelvic floor function, 
physical activity level, physical activity motivation, and your thoughts on participating in 
the study. The questionnaires can be completed in the privacy of your own home and are 
anticipated to take you approximately half an hour to complete. 
 
What do the assessments involve? 
 
As study participant you will undergo the following series of assessments:  
 
 Body Composition & Bone Mineral Density 
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o Dual Energy X-Ray Absorptiometry (DEXA) scan will be used to assess whole 
body composition (fat mass and lean mass) and bone mineral density of the 
hip and spine. These assessments involve lying still on a specially designed 
platform for approximately 10 minutes while a scanning arm will move above 
your total body and above your hip and spine (separate scans for your whole 
body, hip and spine). A low-dosage x-ray will pass from the scanning arm to 
underneath the platform.  
o Peripheral Quantitative Computed Tomography (pQCT) will be used to 
measure muscle density and muscle cross-sectional areas of the lower limb. 
The assessment involves you sitting in a chair with your leg extended and the 
circular scanning arm moving from your ankle to your knee.   
 
The total radiation dose for all scans undertaken during the study is very low, only a 
little more than normal background radiation from an airplane flight and much less 
than, for example, an international flight.  
 
 Physical Activity Level 
 You will be asked to wear an activity monitor (triaxial accelerometer) for a 7-day 
period in order to accurately measure your physical activity levels (i.e. how long you 
are active for in a day). The device is very small (4.6cm x 3.3cm x 1.5cm), lightweight 
(19g) and can be attached to your belt or worn around your waist using a strap. 
 
  Physical Function 
 A series of tests will be used to assess physical function. Before physical function 
tests are performed, you will receive detailed instructions regarding all tests. Where 
necessary, demonstrations, practice time and sufficient warm-up will be undertaken. 
All tests will be supervised by the chief investigator, an accredited exercise 
physiologist, and your safety will be observed at all times. These tests involve: 
 
o 6-meter walk: You will be asked to walk 6 meters at your usual pace and at a 
fast pace (i.e. as if you were running late for an appointment) (performed 3 
times).   
o 6-meter backwards walk: As a test of balance, you will be asked to walk 
backwards in a toe-to-heel fashion for 6 meters (performed 3 times). 
o 400-meter corridor walk: You will be asked to walk 20 meters in a corridor, 
turn around and walk back to the starting position for a total of 10 times. 
o Chair rise: You will be seated in a hard-backed chair and asked to rise and sit 5 
consecutive times, as fast as you can safely do so, without the use of your 
arms for support (performed 3 times). 
o Muscle strength: You will be asked to perform an upper and lower body one 
repetition maximum test. During the one repetition maximum test you will be 
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asked to lift increasingly heavy weights on a chest press and leg extension 
weight-training machine until you reach the most weight you can lift once 
using correct technique. In addition, you will be asked to perform a hand-grip 
strength test, which entails squeezing a hand dynamometer as hard as 
possible. Adequate rest will be provided in between tests to avoid fatigue. 
 
You will be asked to do these assessments twice in two testing sessions (outlined below) 
no less than 6 but no more than 14 days apart. The purpose of the first testing session is 
to familiarise you with all functional assessments in order to minimise any potential 
learning effect. All testing will be conducted at the Edith Cowan University Health and 
Wellness Institute in Joondalup (see map included) and will take approximately 2-3 
hours.  
 
OUTLINE OF TESTING SESSIONS 
Session 1 Session 2 (6-14 days after Session 1) 
The chief investigator will  
 review consent forms, demographic 
and health history questionnaire and 
study procedures with you 
 hand out quality of life, pelvic floor 
function and physical activity 
questionnaires 
 provide you with an activity monitor 
 measure your height and weight 
  
The chief investigator will 
 review quality of life, pelvic floor 
function and physical activity 
questionnaires with you 
 collect the activity monitor from you 
 provide verbal feedback and (optional) 
exercise counselling to you after 
conducting all tests 
 
You will undergo a DEXA and pQCT scan.  
You will undergo functional testing: 
 6-Meter walk test 
o Usual pace forward 
o Fast pace forward 
o Toe-to-heel backward 
You will undergo functional testing: 
 6-Meter walk test 
o Usual pace forward 
o Fast pace forward 
o Toe-to-heel backward 
 400-Meter walk test  400-Meter walk test 
 Chair raise  Chair raise 
 Muscle strength testing 
o One repetition maximum 
tests 
o Grip strength test 
o  
 Muscle strength testing 
o One repetition maximum tests 
o Grip strength 
How long will it take? 
 2.5 hours for assessment 
 30 minutes at home to complete 
questionnaires 
 
How long will it take? 
 1 hours for assessment 
 30 minutes for (optional) exercise 
counselling 
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What are the possible benefits of participating?  
The direct benefit for you is that all study activities, including all assessments, are provided 
at no cost to you. At the end of the second testing session the chief investigator will provide 
feedback regarding your test results.  You will then be offered the choice of either: 
 No exercise consultation, OR 
 A brief 30-minute exercise consultation with the chief investigator immediately after 
the second  testing session, OR 
 A more comprehensive 60-minute exercise consultation with the chief investigator 
on another day at a time agreeable to both parties. 
 
During the consultation of your choice the chief investigator will make exercise 
recommendations based on your test results and answer any exercise related questions you 
may have. Additionally, it is hoped that this study will contribute important new information 
that will be useful in the management of ovarian cancers and long-term treatment side 
effects. 
 
What are the possible side effects and risks?  
 
Prior to any testing, your GP will review your medical history and the study protocols to 
make sure that you are medically ready for the study procedures. However, any strength 
and physical functional testing may result in mild discomfort and muscle soreness. There is 
also the possibility of muscle pulls or strains, common to any type of physical activity. Risk of 
falling may exist in the performance of some tasks. In order to minimize these risks you will 
be thoroughly familiarized with the movements involved in this investigation through 
comprehensive instructions and demonstrations, and supervised at all times by the chief 
investigator, an accredited exercise physiologist. Furthermore, during exercise testing it is 
possible to experience symptoms such as abnormal blood pressure, fainting, light-
headedness, nausea, and in very rare cases heart rhythm disturbances or heart attack. 
These potential risks are common to any form of physical activity. You will be asked to 
report any symptoms you experience during exercise testing and your safety will be of 
primary importance at all times. In the event that an emergency occurs, medical assistance 
will be obtained according to established emergency procedures at the ECU Health and 
Wellness Institute.  
 
DEXA and pQCT scans are routine clinical tests, but carry a small risk to you as they involve 
exposure to radiation. The level of radiation exposure is exceedingly small (10-30 
microSieverts [µSv]) in comparison to the natural annual radiation dose in western 
communities (approximately 3000 µSv).  A person would receive radiation exposure of 
approximately 80 µSv on an airline flight of 8 hours or 30 to 40 µSv during a typical chest x-
ray.  
 
You may experience some discomfort in answering the items in the questionnaires. Your 
responses will be kept strictly confidential. Some of the questions will ask about the level of 
distress you are experiencing. If our study identifies that you are experiencing significant 
distress you will be contacted and your permission will be sought to inform your GP or 
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cancer specialist so that referral to appropriate services can be made. In addition, if you 
should experience and express any distress at any stage during participation in the study, 
the chief investigator will offer you the opportunity to contact a support person of your 
choice (i.e. your husband or a friend). It is also recommended that you obtain permission 
from your GP to be contacted if you feel you would rather contact him/her in case you 
experience significant distress. 
 
Privacy and confidentiality 
 
The conduct of this research involves the collection, access and/or use of your identified 
personal information. The information collected is confidential and will not be disclosed to 
third parties without your consent, except to meet government, legal or other regulatory 
authority requirements. A de-identified copy of this data may be used for other research 
purposes.  
However, your anonymity will be safeguarded at all times. Participants will not be referred 
to by name in research reports or during study discussions. If the results of the study are 
published in a scientific journal, as is intended, no reader will be able to identify individual 
patients. All records will be stored in a locked filing cabinet in a private office on the 
Joondalup campus of Edith Cowan University with restricted access for a minimum of five 
years.  All computer records are restricted by password.  
Are there any costs involved? 
 
If you choose to participate in the study, you will be asked to attend two testing sessions at 
ECU in Joondalup.  Parking for visitors is available on campus at a cost of $1.50 per hour. 
The parking permit included in the package will allow you access to the Health and Wellness 
Institute’s parking area close to the building where you will undergo testing (indicated on 
the included campus map). Please note that you still have to pay for parking and that tickets 
can be purchased at vending machines located in the parking area.  To help cover travel and 
parking expenses, you will be provided with a $25.00 voucher at your second testing 
session.  
 
Will I receive any feedback? 
 
You will receive verbal feedback regarding your test results at the end of the second testing 
session. If you would like to discuss your results and ask questions about exercise, you have 
the choice of either a brief 30-minute exercise consultation with the chief investigator 
immediately after the second session or a more comprehensive 60-minute exercise 
consultation on another day at a time agreeable to both parties. During the consultation of 
your choice the chief investigator will make exercise recommendations based on your test 
results and answer your exercise-related questions. A summary of study results will be made 
available to all interested participants upon completion of the study.  
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Contacting the investigators  
 
We are happy to answer any questions you may have at this time. If you have any queries 
later, please do not hesitate to contact either: 
Mrs Christelle Schofield  Phone: 0459 900 264             E-mail: c.schofield@ecu.edu.au 
Prof Robert Newton   Phone: (08) 6304 3443          E-mail: r.newton@ecu.edu.au 
 
Independent Contact Person 
 
The ECU Human Research Ethics Committee and the Human Research Ethics Committee at 
St John of God Hospital, Subiaco have approved this project. If you have any concerns or 
complaints about the research project and wish to talk to an independent person, you may 
contact: 
 
Research Ethics Officer 
Edith Cowan University 
270 Joondalup Drive 
JOONDALUP WA 6027 
Phone: (08) 6304 2170 
Email: research.ethics@ecu.edu.au 
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ECU Health & Wellness Institute is located in building 21 on the Joondalup Campus of Edith 
Cowan University. 
• Please come to the Institute entrance located between building 21 and building 19 and 
check in with reception. 
• Parking is available for ECU Health & Wellness Institute clients directly behind building 19. 
• Parking charges are $1.50 p/hour. 
• If you have any problems locating the parking area please contact Christelle on 0459 
900 264. 
DIRECTIONS FROM THE FREEWAY: 
• Take the Hodges Drive exit 
• Turn Right onto Hodges Drive 
• Turn right onto Joondalup Drive 
• Turn left onto Lakeside Drive 
• Turn left onto Chancellors Pass 
• Turn left at the round-a-bout 
• Take the first right into the Institute Client Car Park (will be to your right) 
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MEDICAL DOCTOR CONSENT FORM  
 
             Project Title: Physiological and disease specific characteristics of  
      ovarian cancer survivors 
 
Researchers:  
Mrs Christelle Scofield, Masters Student - E: c.schofield@ecu.edu.au - T: 0459 900 264 
Prof Robert Newton, PhD - E: r.newton@ecu.edu.au - T: (08) 6304 5037 
Dr Carolyn McIntyre, PhD - E: c.mcintyre@ecu.edu.au - T: (08) 6304 3987  
Prof Daniel Galvão, PhD - E: d.galvao@ecu.edu.au - T: (08) 6304 3420  
 
Institute: Edith Cowan University Health and Wellness Institute 
      St John of God, Subiaco 
 
Dear Doctor,  
 
The Edith Cowan University Health and Wellness Institute is undertaking a research study in 
collaboration with The St John of God Gynaecologic Oncology research group investigating the 
physiological and disease specific characteristics of ovarian cancer survivors. Women with 
ovarian cancer often experience a significant burden of disease and treatment side-effects. 
Exercise has been acknowledged as a safe and effective supportive care intervention for cancer 
survivors. Currently it is unknown what exercise is most appropriate for women with ovarian 
cancer to address their disease and treatment specific adverse side-effects. To better 
understand their exercise needs and to design appropriate exercise interventions for both 
research and clinical settings, we aim to identify unique physiological and disease specific 
characteristics of women with ovarian cancer. The purpose of this study is to determine the 
physiological and disease specific characteristics of ovarian cancer survivors and to explore 
differences in physiological characteristics between women with ovarian cancer and similarly 
aged women who have never been diagnosed with cancer.  
Outcome measures in the study: 
 Self-reported and objectively measured physical function. Objective physical function tests 
include:  
o muscle strength - measured by a 1-RM (repetition maximum) bench press and   single 
leg extension test, as well as by a handgrip strength test 
o gait speed - measured by a 6-meter normal and fast pace walk  
o dynamic balance - measured by a 6-meter backwards walk 
o ability to get up from and sit back down in a chair – measured by a chair rise test 
Appendix J –Medical consent- cancer survivors 
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o cardiorespiratory fitness and mobility – measured by a 400-meter walk (not on a 
 treadmill) 
 Self-reported and objective (measured by an accelerometer) physical activity 
 Body composition (total and trunk fat mass, lean mass, bone mineral density), muscle 
density and bone strength – measured by DEXA and pQCT scans respectively 
 Self-reported pelvic floor function 
 
 Information obtained from this research will assist health professionals in making exercise 
recommendations and in designing the most appropriate exercise interventions for ovarian 
cancer survivors. 
 
As ovarian cancer survivors (cancer group) will be compared to similarly aged women who 
have never been diagnosed with cancer (control group), two groups of 22 participants each 
are required for the study. Your patient has expressed interest to participate in the cancer 
group of the study.  
Participants for the cancer group must meet all the following criteria:  
 Histologically confirmed stage III – IV ovarian cancer  
 No evidence or suspicion of bone metastasis 
 Be 18 years or older 
 Not have had cancer-related treatment during the last 3 months (e.g. surgery, 
chemotherapy   and/or radiation therapy)  
 Not have completed cancer-related treatment more than 24 months ago 
 No acute illness at the time of testing or any musculoskeletal, cardiovascular or             
neurological disorder that could put the participant at risk of injury or illness during 
exercise testing 
 
The study has been approved by the Human Research Ethics Committees at Edith Cowan 
University and St John of God Hospital, Subiaco and subjects will be free to withdraw from 
the study at any time.  
 
The concern of the researchers is of past and/or present medical conditions that may 
compromise the individual’s ability to participate in the exercise testing involved with this 
study, as described above. For these reasons all potential participants have been asked to 
seek their medical doctor’s approval prior to involvement in the study.  
 
 
 _______________________ is in sufficient health to participate in this study.  
Participant’s Name  
 
 
_______________________            ______________________              ___________  
Doctors Name (please print)     Doctors Signature                     Date 
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Please complete this letter and return it, along with any relevant records via facsimile to 
Mrs Christelle Schofield on 08 9206 3807 at your earliest convenience, or by hand to the 
participant. 
 
If you would like to refer patients, or if you require more information, please feel free to 
contact me or any of my supervisors. We will be happy to provide study outcomes to you as 
per your request. 
 
Yours sincerely 
 
 
 
 
Christelle Schofield (AEP ESSAM) 
Master of Science (Exercise Science) Student 
Edith Cowan University Health and Wellness Institute 
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MEDICAL DOCTOR CONSENT FORM  
 
             Project Title: Physiological and disease specific characteristics of  
       ovarian cancer survivors 
 
Researchers:  
Mrs Christelle Scofield, Masters Student - E: c.schofield@ecu.edu.au - T: 0459 900 264 
Prof Robert Newton, PhD - E: r.newton@ecu.edu.au - T: (08) 6304 5037 
Dr Carolyn McIntyre, PhD - E: c.mcintyre@ecu.edu.au - T: (08) 6304 3987  
Prof Daniel Galvão, PhD - E: d.galvao@ecu.edu.au - T: (08) 6304 3420  
 
Institute: Edith Cowan University Health and Wellness Institute 
            St John of God, Subiaco 
        
Dear Doctor,  
 
The Edith Cowan University Health and Wellness Institute is undertaking a research study in 
collaboration with The St John of God Gynaecologic Oncology research group investigating 
the physiological and disease specific characteristics of ovarian cancer survivors. Women 
with ovarian cancer often experience a significant burden of disease and treatment side-
effects. Exercise has been acknowledged as a safe and effective supportive care intervention 
for cancer survivors. Currently it is unknown what exercise is most appropriate for women 
with ovarian cancer to address their disease and treatment specific adverse side-effects. To 
better understand their exercise needs and to design appropriate exercise interventions for 
both research and clinical settings, we aim to identify unique physiological and disease 
specific characteristics of women with ovarian cancer. The purpose of this study is to 
determine the physiological and disease specific characteristics of ovarian cancer survivors 
and to explore differences in physiological characteristics between women with ovarian 
cancer and similarly aged women who have never been diagnosed with cancer.  
 
Outcome measures in the study: 
 Self-reported and objectively measured physical function. Objective physical function 
tests include:  
o muscle strength - measured by a 1-RM (repetition maximum) bench press and     
single leg extension test, as well as by a handgrip strength test 
o gait speed - measured by a 6-meter normal and fast pace walk  
o dynamic balance - measured by a 6-meter backwards walk 
o ability to get up from and sit back down in a chair – measured by a chair rise test 
Appendix K –Medical consent- control 
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o cardiorespiratory fitness and mobility – measured by a 400-meter walk (not on a 
 treadmill) 
 Self-reported and objective (measured by an accelerometer) physical activity 
 Body composition (total and trunk fat mass, lean mass, bone mineral density), muscle 
density and bone strength – measured by DEXA and pQCT scans respectively 
 Self-reported pelvic floor function 
 
 Information obtained from this research will assist health professionals in making exercise 
recommendations and in designing the most appropriate exercise interventions for ovarian 
cancer survivors. 
 
As ovarian cancer survivors (cancer group) will be compared to similarly aged women who have 
never been diagnosed with cancer (control group), two groups of 22 participants each are 
required for the study. Your patient has expressed interest to participate in the control group of 
the study.  
 
Participants for the control group must meet all the following criteria:  
 Be 18 years or older 
 Have never had a diagnosis of cancer or history of cancer (other than non-melanoma skin 
cancer) 
 Must not have an acute illness at the time of testing or any musculoskeletal, cardiovascular 
or neurological disorder that could put the participant at risk of injury or illness during 
exercise testing 
 
The study has been approved by Human Research Ethics Committees at Edith Cowan University 
and St John of God Hospital, Subiaco and subjects will be free to withdraw from the study at any 
time.  
 
The concern of the researchers are of past and/or present medical conditions that may 
compromise the individual’s ability to participate in the exercise testing involved with this 
study, as described above. For these reasons all potential participants have been asked to seek 
their medical doctor’s approval prior to involvement in the study.  
 
 
 
   __________________ is in sufficient health to participate in this study.  
Participant’s Name  
 
 
 
_______________________            ______________________              ___________  
Doctors Name (please print)     Doctors Signature                     Date 
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Please complete this letter and return it, along with any relevant records via facsimile to Mrs 
Christelle Schofield on 08 9206 3807 at your earliest convenience, or by hand to the participant. 
 
If you would like to refer patients, or if you require more information, please feel free to contact 
me or any of my supervisors. We will be happy to provide study outcomes to you as per your 
request. 
 
Yours sincerely 
 
 
 
 
Christelle Schofield (AEP ESSAM) 
Master of Science (Exercise Science) Student 
Edith Cowan University Health and Wellness Institute 
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PARTICIPANT CONSENT FORM  
 
Physiological and disease specific characteristics of 
ovarian cancer survivors 
 
 
Participant Name:   
 
 I have read and understood the information letter and this participant consent form.   
 I understand that the study will be carried out as described in the information letter, a copy 
of which I have retained. 
 I have obtained approval from my doctor to complete the activities required for participation 
in the study. 
 The nature and possible effects of the study have been explained to me. 
 Any questions that I have asked have been answered to my satisfaction. 
 I understand that all research data will be treated as confidential. 
 I agree to participate in this study and give my consent freely.   
 I realise that my participation in this research study is voluntary and whether or not I decide 
to participate is solely my decision.   
 I also realize that I can withdraw from the study at any time and that I do not have to give 
any reasons for withdrawing.   
 I agree that research data gathered for the study may be published provided my name or 
other identifying information is not disclosed.   
 
Participant: 
 
______________________   ______________________          ___________ 
Name     Signature     Date  
 
Witness:  
 
______________________   ______________________          ___________ 
Name     Signature     Date 
 
  
Appendix L – Participant consent form 
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DEMOGRAPHIC INFORMATION 
AND HEALTH HISTORY 
QUESTIONNAIRE 
 
 
 
______________________________     _____________________________________      
First Name          Last Name                   Middle Initial 
 
 
___________________           _________           _______________________           
Date of Birth             Age                 Sex                
 
 
_______________________________________________________________________________ 
 
_______________________________________________________________________________ 
Postal Address 
 
 
____________________    ____________________________    ____________________________ 
Home Phone            Mobile Phone            Email Address 
 
 
_________________________________              ________________________________________ 
Family Physician Name           Practice or Phone Number 
 
 
_______________________    ____________________________    _________________________ 
Emergency Contact Name    Phone Number                   Relationship  
 
 
1. What is your current marital status? 
 
Single     Married    Defacto 
 
Separated    Divorced    Widowed 
 
 
2. What is the highest level of education you have completed? 
 
Primary    Secondary    Trade 
 
Certificate/Diploma   Bachelor degree   Higher degree 
 
 
ID No: _________ Initials: _________ 
Date:  
__________________________ 
Appendix M – demographic information and health 
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Other 
______________________________________________________________________ 
 
3. What is your current level of employment (please circle)? 
 Retired            Unemployed            Casual            Part-time            Full time            Volunteer 
          If employed, what is your current occupation? 
_______________________________________ 
          If employed, how many hours/days do you work in a typical week?   
 ____________ hours/day 
____________ days/week 
4. Are you or have you ever been a smoker?  Yes    No 
If yes: 
a. Are you a past or current smoker? 
______________________________________ 
b. Age you started smoking: 
_____________________________________________ 
c. Age you quit smoking (for past smokers only): 
____________________________ 
d. Average number of cigarettes smoked per day: 
___________________________ 
 
5. How many alcoholic drinks do you usually have per week? 
_____________________________ 
 
 
6. Has your weight fluctuated more than a few kilos in the last 12 months?   
Yes    No 
a. If yes, has your weight gone up or down?   __________________________ 
b. Approximately how many kilograms?  ______________________________ 
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7. Do you experience shortness of breath while walking with others of your age?      Yes       No 
 
8. Do you experience sudden tingling, numbness, or loss of feeling in arms, hands, legs, feet, 
or face?       Yes    No 
 
9. Do you experience swelling of your feet and ankles?      Yes    No 
 
10. Do you get pains or cramps in your legs?        Yes    No 
 
11. Do you experience any discomfort in your chest?       Yes    No 
 
12. Have you ever been told that your blood pressure was abnormal?  Yes    No 
If yes, do you currently take any medication (please provide details)? 
________________________________________________________________________ 
________________________________________________________________________ 
 
13. Have you ever been told that your serum cholesterol or triglyceride level was high?     
Yes     No 
If yes, do you currently take any medication (please provide details)? 
____________________________________________________________________________
____________________________________________________________________________ 
 
14. Have you ever been told that you have cardiovascular disease?  Yes    No 
If yes, please provide details of condition and how it is controlled. 
____________________________________________________________________________
____________________________________________________________________________ 
 
15. Have you ever been told that you have diabetes?    Yes    No 
If yes, how is it controlled? 
____________________________________________________________________________
____________________________________________________________________________ 
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16. Have you ever been told that you have osteoporosis?    Yes    No 
If yes, how is it controlled? 
____________________________________________________________________________
____________________________________________________________________________ 
 
17. Has a doctor or nurse ever told you that you had any of the following conditions?         
Heart attack………………….. Yes          No   Stroke……………………… Yes          No 
 
Emphysema………………….. Yes          No   Chronic bronchitis……. Yes          No 
 
Arthritis………………………… Yes          No   Thyroid Disease……….. Yes          No 
 
Peripheral Vascular..……… Yes          No   Angina..……………………. Yes          No  
Disease       (chest pain) 
 
If yes, please provide details 
____________________________________________________________________________                               
____________________________________________________________________________
____________________________________________________________________________ 
 
18. When were you diagnosed with cancer?      Month: ________________    Year: ___________  
 
19. What form of gynaecological cancer have you been diagnosed with? 
_______________________________________________________________________________ 
 
20. Have you been diagnosed with a secondary cancer?    Yes  No  
a. If yes, what form? 
___________________________________________________________________ 
b. When? 
___________________________________________________________________ 
 
21. Which types of treatment have you undertaken? (circle all that apply) 
 
 Surgery      Radiation         Chemotherapy                    
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Please indicate if you have received any other the type of treatment 
_______________________________________________________________________________ 
 
22. Please specify the start date, duration and other important details of each treatment  
Surgery (if applicable) 
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
Chemotherapy (if applicable) 
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
Radiation (if applicable)   
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
 
23. In addition to the above, do you have any other medical conditions (chronic or serious 
illness)?   Yes  No 
If yes, please provide details:  
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
____________________________________________________________________________ 
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24. Please list below the prescription medications you are currently taking. Fill out every 
column for each medication you list. 
Medication Duration 
(in years and months) 
Reason for taking (i.e. which 
medical condition) and other 
comments 
   
   
   
   
   
   
   
 
 26. Have you ever had any surgery (unrelated to cancer)   Yes   No  
If yes, please provide details about the type, date and reason for the surgery  
Type of Surgery Date of Surgery  
(month & year) 
Reason for Surgery & details of any 
continuing impairments 
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DAY 1 – ASSESSMENT 
 
Appointment Details 
 
Date:   Please call Christelle Schofield on 0459 900 264 to arrange an assessment 
date at your convenience after you have received permission from your 
doctor to take part in the study. 
 
Venue:  Edith Cowan University, Health and Wellness Institute 
 Level 2, Building 21 
 270 Joondalup Drive 
 Joondalup, WA, 6027 
 
Parking: Visitor Car Parking is available in Car Park 13 next to the Health and 
Wellness Institute at $1.50 per hour. (Enter off Lakeside Drive). Please 
display your purchased parking ticket as well as the parking permit included 
in this package on your vehicle’s dashboard.  
 
 
It would be advisable to remove all jewellery and wear loose, unrestrictive clothing and 
training shoes to both assessment sessions if possible.  
 
 
Things to remember: 
 Please eat your breakfast and take any medications as usual. 
 
 Please bring 
o change for parking 
o the signed letter from your specialist/GP  
o your signed consent form  
o the completed Demographic and Health History Questionnaire 
 
 If you use a hearing aid or glasses, please ensure you have them with you on the 
day. 
 
 Wear clothing and footwear suitable for exercise. 
 
The DAY 1 schedule will involve: 
 Information about the study and time for asking questions 
 Review of questionnaires (please bring your reading glasses) 
 DEXA  and PQCT scans of your bone density and body composition  
 Tests of your physical performance 
 
 
If a problem arises on the day (for example you are running late or get lost), please 
contact Christelle on 0459 900 264. 
 
  
Appendix N – Day 1 letter 
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ACTIVITY MONITOR INSTRUCTIONS 
 
The activity monitor measures the amount of physical activity you do in your 
everyday life.  It is also used to measure the amount and quality of your sleep.  
  
1. Please start wearing the monitor from:  
 
_________________________________________________  
 
2.  Please take off the monitor: 
 
_________________________________________________  
 
If you have any questions about the activity monitor please call the chief study 
investigator, Christelle Schofield, on 0459 900 264. 
 If there is no answer, please leave a message. Your call will be responded to as 
soon as possible. 
 
Where do I wear the activity monitor? 
o The monitor needs to be worn at the hip area of your waist with the 
black button facing the top (Do not twist the button). 
o The monitor can be worn either above or beneath clothing, and it is not 
necessary for it to make contact with the skin.  
o The monitor must be held snugly against the body to work properly (i.e. must 
be secure and not bounce or slide when you’re moving). 
 
 How long do I wear the activity monitor for? 
o We ask that you wear the monitor for a period of 7 days. 
o To get the most accurate information, it is very important to wear the 
monitor 24 hours a day if possible. 
o This includes when you are asleep at night. 
o The monitor should be taken off to bath/shower.  
o You need to take off the activity monitor on the date and time listed 
above. 
 
 
 
Appendix O - Activity monitor instructions 
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 What happens if I get the activity monitor wet? 
o It’s preferable if the monitor doesn’t get wet, but it is water resistant and 
will not be affected by getting slightly wet. 
o If you are a swimmer please take the device off before getting into the 
pool/ocean.   
o Note the device is water resistant and not water proof. 
 
 How do I return the monitor? 
o If you complete the 7-day period before your second assessment, please 
bring the monitor with you when you return to the ECU Health and 
Wellness Institute for your second assessment.  
o If you complete the 7-day period after your second assessment you will 
be provided with a prepaid envelope to post the monitor back to the 
Institute via any red Australia Post mailbox. 
o  If you choose to withdraw from the study after the first assessment and 
after you have received the monitor, Christelle will contact you to make 
arrangements for the monitor to be returned to the Institute. 
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ACTIVITY MONITOR LOG  
 
Study ID: __________  
 
Date: ____/____/____ 
 
Please use this form to document any time that you didn’t wear the monitor during the 7-
day period, or any issues you had wearing the monitor. 
 
  
 
DETAILS 
Day 1  
Day 2  
Day 3  
Day 4  
Day 5  
Day 6   
Day 7  
Appendix P - Activity monitor log 
137 
 
 
 
  
QUESTIONNAIRES 
 
Name: ______________________________________   Date: ___________________ 
 
 Please take your time completing these important questionnaires and answer all 
questions as honestly as you can. Please note that there are questions on both 
sides of each page in this package. 
 
 Your responses provide extremely valuable information regarding the impact of 
cancer and cancer-related treatment on cancer survivors and have the potential to 
influence the information and services provided to all cancer survivors and 
specifically ovarian cancer survivors worldwide. 
 
 We really appreciate your time and value the contribution you are making to 
advancing the scientific knowledge surrounding the exercise needs of ovarian 
cancer survivors. 
  
 If you have any questions whatsoever don’t hesitate to contact: 
 Christelle Schofield 
 Chief Study Investigator 
 Phone: 0459 900 264 
 E-mail: c.schofield@ecu.edu.au 
 
 Please return the questionnaires to Christelle on your next testing session. 
 
THANK YOU! 
Appendix Q - Questionnaires
138 
 
YOUR HEALTH AND WELL-BEING 
This questionnaire asks for your views about your health. This information will help keep track of 
how you feel and how well you are able to do your usual activities. For each of the following 
questions, please circle the one number that best describes your answer. 
1. In general, would you say your current health is: 
Excellent Very Good Good Fair Poor 
1 2 3 4 5 
 
2. Compared to one year ago, how would you rate your health in general now? 
Much better 
now than one 
year ago 
Somewhat 
better now than 
one year ago 
About the same 
as one year ago 
Somewhat 
worse now than 
one year ago 
Much worse 
now than one 
year ago 
1 2 3 4 5 
 
3. The following questions are about activities you might do during a typical day. Does your 
health now limit you in these activities? If so, how much? 
 Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
a) Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports. 
1 2 3 
b) Moderate activities, such as moving a table, pushing 
a vacuum cleaner, bowling, or playing golf. 
1 2 3 
c) Lifting or carrying groceries. 1 2 3 
d) Climbing several flights of stairs. 1 2 3 
e) Climbing one flight of stairs. 1 2 3 
f) Bending, kneeling, or stooping. 1 2 3 
g) Walking more than a mile. 1 2 3 
h) Walking several hundred yards. 1 2 3 
i) Walking one hundred yards. 1 2 3 
j) Bathing or dressing yourself 1 2 3 
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4. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of your physical health?  
 All of 
the 
time 
Most 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
a) Cut down on the amount of time you spent 
on work or other activities.  
1 2 3 4 5 
b) Accomplished less than you would like. 1 2 3 4 5 
c) Were limited in the kind of work or other 
activities. 
1 2 3 4 5 
d) Had difficulty performing the work or other 
activities (for example, it took extra effort). 
1 2 3 4 5 
 
5. During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of any emotional problems (such as 
feeling depressed or anxious)? 
 All of 
the 
time 
Most of 
the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
a) Cut down on the amount of time you 
spent on work or other activities. 
1 2 3 4 5 
b) Accomplished less than you would like. 1 2 3 4 5 
c) Did work or other activities less carefully 
than usual. 
1 2 3 4 5 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours, or groups? 
Not at all Slightly Moderately Quite a bit Extremely 
1 2 3 4 5 
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7. How much bodily pain have you had during the past 4 weeks? 
None Very mild Mild Moderate Severe Very severe 
1 2 3 4 5 6 
 
 
8. During the past 4 weeks, how much did pain interfere with your normal work (including both 
work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely 
1 2 3 4 5 
 
 
9. These questions are about how you feel and how things have been with you during the past 4 
weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling. How much of the time during the past 4 weeks… 
 All of 
the 
time 
Most of 
the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
a) Did you feel full of life? 1 2 3 4 5 
b) Have you been very nervous? 1 2 3 4 5 
c) Have you felt so down in the dumps that 
nothing could cheer you up? 
1 2 3 4 5 
d) Have you felt calm and peaceful? 1 2 3 4 5 
e) Did you have a lot of energy? 1 2 3 4 5 
f) Have you felt downhearted and 
depressed? 
1 2 3 4 5 
g) Did you feel worn out? 1 2 3 4 5 
h) Have you been happy? 1 2 3 4 5 
i) Did you feel tired? 1 2 3 4 5 
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10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives, etc.)? 
All of the time Most of the time 
Some of the 
time 
A little of the 
time 
None of the time 
1 2 3 4 5 
 
 
11. How TRUE or FALSE is each of the following statements for you? 
 Definitely 
true 
Mostly 
true 
Don't 
know 
Mostly 
false 
Definitely 
false 
a) I seem to get sick a little easier 
than other people.  
1 2 3 4 5 
b) I am as healthy as anybody I know. 1 2 3 4 5 
c) I expect my health to get worse. 1 2 3 4 5 
d) My health is excellent. 1 2 3 4 5 
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PHYSICAL ACTIVITY LEVEL 
 
For this next question, we would like you to recall your average weekly exercise in the PAST 
MONTH.  
 
When answering these questions please: 
 Only count exercise sessions that lasted 10 minutes or longer in duration. 
 Only count exercise that was done during free time (i.e., not occupation or housework). 
 Note that the main difference between the three categories is the intensity of the 
exercise. 
 
 
1. Considering a typical week (7 days) how many times on the average did you do the following 
kinds of exercise in the PAST MONTH? 
 
        
     
             Average Frequency   Average Duration 
 
a. STRENUOUS EXERCISE    ________times/week        _______ minutes 
(HEART BEATS RAPIDLY, SWEATING) 
(e.g. running, aerobics classes,  
vigorous swimming, vigorous bicycling). 
 
 
b. MODERATE EXERCISE     _______ times/week        _______ minutes 
(NOT EXHAUSTING, LIGHT PERSPIRATION)  
(e.g. fast walking, tennis, easy bicycling, 
easy swimming, popular and folk dancing). 
 
 
c. MILD EXERCISE  ________ times/week   _______ minutes  
(MINIMAL EFFORT, NO PERSPIRATION) 
(e.g. easy walking, yoga, lawn bowling,). 
 
 
d. RESISTANCE EXERCISE      ________ times/week        _______ minutes 
(e.g., repetitively lifting weights using    
your own body weight, dumbbells, weight  
machines, or resistance bands) 
 
 
 
2. During a typical 7-Day period (a week), in your leisure time, how often do you engage in any 
regular activity long enough to work up a sweat (heart beats rapidly)? 
 
Often Sometimes Never/Rarely 
1 2 3 
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PELVIC FLOOR FUNCTION 
For each of the following questions, please circle the one number that best describes your 
answer. 
Consider your experiences during the last month. 
Bladder function 
1. How many times do you pass urine in the day? 
 
Up to 7  between 8 and 10 between 11 and 15 more than 15 
0 1 2 3 
 
2. How many times do you get up at night to pass urine? 
 
0-1 2 3 More than 3 
0 1 2 3 
 
3. Do you wet the bed before you wake up at night? 
never 
 
occasionally (less than 
once per week) 
frequently (once or 
more per week) 
always (every night) 
 
0 1 2 3 
 
4. Do you need to rush or hurry to pass urine when you get the urge? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
5. Does urine leak when you rush or hurry to the toilet or can’t you make it in time? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
6. Do you leak urine with coughing, sneezing, laughing or exercising? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
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7. Is your urinary stream (urine flow) weak, prolonged or slow? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
8. Do you have a feeling of incomplete bladder emptying? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
9. Do you need to strain to empty your bladder? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
10.  Do you have to wear pads because of urinary leakage? 
 
never As a precaution When exercising 
/during a cold 
 daily 
 
0 1 2 3 
 
11. Do you limit your fluid intake to decrease urinary leakage? 
 
never before going out moderately 
 
always 
 
0 1 2 3 
 
12. Do you have frequent bladder infections? 
 
no 1-3 per year 4-12 per year more than 1 per 
month 
0 1 2 3 
 
13. Do you have pain in your bladder or urethra when you empty your bladder? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
145 
 
 
14. Does urine leakage affect your routine activities like recreation, socialising, sleeping, shopping   etc.? 
not at all slightly moderately  greatly 
 
0 1 2 3 
 
15. How much does your bladder problem bother you? 
not at all slightly moderately  greatly 
 
0 1 2 3 
 
Bowel function 
16. How often do you usually open your bowels? 
every other day or 
daily 
less than every 3 days 
 
less than once per 
week 
 more than once per 
day 
0 1 2 3 
 
17. How is the consistency of your usual stool? 
soft, firm or hard (pebbles) variable watery 
0 1 2 
 
18. Do you have to strain a lot to empty your bowels? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
19. Do you use laxatives to empty your bowels? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
20. Do you feel constipated? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
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21. When you get wind or flatus, can you control it or does wind leak? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
22. Do you get an overwhelming sense of urgency to empty your bowels? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
23. Do you leak watery stool when you don’t mean to? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
24. Do you leak normal stool when you don’t mean to? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
25. Do you have a feeling of incomplete bowel emptying? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
26. Do you have to use finger pressure to help empty your bowels? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
27. How much does your bowel problem bother you? 
not at all slightly moderately  greatly 
 
0 1 2 3 
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Prolapse symptoms 
28. Do you have a sensation of tissue protrusion or a lump or bulging in your vagina? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
29. Do you experience vaginal pressure or heaviness or a dragging sensation? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
30. Do you have to push back your prolapse in order to void? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
31. Do you have to push back your prolapse to empty your bowels? 
never occasionally (less than 
once per week) 
frequently (once or 
more per week) 
 daily 
 
0 1 2 3 
 
32. How much does your prolapse bother you? 
not at all slightly moderately  greatly 
 
0 1 2 3 
 
Sexual function 
33. Are you sexually active? (please tick the box relevant to you) 
 no 
        less than once per week 
  once or more per week 
 daily or most days 
If you are not sexually active, please continue to answer questions 34 and 42 only 
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34. If you are not sexually active, please tell us why: (please tick the box relevant to you) 
 I do not have a partner 
  I am not interested 
  my partner is unable 
 vaginal dryness 
  too painful  
 embarrassment due to the prolapse or incontinence 
other reasons: _________________________________________ 
 
35. Do you have sufficient natural vaginal lubrication during intercourse? 
yes no       
0 1 
 
36. During intercourse vaginal sensation is: 
normal/pleasant minimal painful none 
 
0 1 1 3 
 
37. Do you feel that your vagina is too loose or lax? 
never occasionally frequently  always 
 
0 1 2 3 
 
38. Do you feel that your vagina is too tight? 
never occasionally frequently  always 
 
0 1 2 3 
 
39. Do you experience pain with sexual intercourse? 
never occasionally frequently  always 
 
0 1 2 3 
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40. Where does the pain during intercourse occur? 
Not applicable, I do 
not have pain 
at the entrance to the 
vagina 
deep inside, in the 
pelvis  
 both at the entrance 
and in the pelvis  
0 1 2 3 
 
41. Do you leak urine during sexual intercourse? 
never occasionally frequently  always 
 
0 1 2 3 
 
42. How much do these sexual issues bother you? 
 not applicable, I do not have problems 
not at all slightly moderately  greatly 
 
0 1 2 3 
 
 Baessler K., O’Neill S.M., Maher C.F., Battistutta D. (2010) A validated self-administered female pelvic floor 
questionnaire. Int Urogynecol  J 21: 163-172 
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YOUR FEELING ABOUT EXERCISE  
 
The following questions ask you to rate how you feel about exercising on your own over the next 
month. Please note that this study is not an exercise intervention study. However, the 
information you provide regarding your feelings about exercise will be extremely useful in the 
design and implementation of exercise intervention programs for women with ovarian cancer.  
 
Exercise, for the purpose of the questionnaire, is defined as planned, structured and repetitive 
activity with the purpose to improve or maintain physical fitness and health. It excludes 
occupational, household and leisure activities. Ideally an exercise program should consist of: 
 2 strength or resistance training sessions/week using for instance your own body weight, 
weight machines, resistance bands or dumbbells. 
 150 minutes of moderate intensity aerobic-type exercise/week, for instance brisk 
walking, cycling, swimming or tennis. 
 Stretching exercises for mobility. 
 
Please pay careful attention to the words and descriptors at the end of each scale and circle the 
number that best represents how you feel. Please answer all items from (a) to (f). 
I think that doing exercise over the next month would be: 
 
(a) 
 
(b) 
 
(c) 
 
(d)  
 
 
 
1 2 3 4 5 6 7 
Extremely 
Useless 
Quite   
Useless 
Slightly  
Useless 
Neutral Slightly 
Useful 
Quite Useful Extremely 
Useful 
1 2 3 4 5 6 7 
Extremely 
Unenjoyable 
Quite  
Unenjoyable 
Slightly 
Unenjoyable  
Neutral Slightly 
Enjoyable 
Quite  
Enjoyable 
Extremely 
Enjoyable   
1 2 3 4 5 6 7 
Extremely 
Harmful 
Quite 
Harmful    
Slightly  
Harmful 
Neutral Slightly 
Beneficial 
Quite 
  Beneficial   
Extremely  
Beneficial 
1 2 3 4 5 6 7 
Extremely 
Painful 
Quite 
Painful    
Slightly  
Painful 
Neutral Slightly 
Beneficial 
Quite 
  Beneficial   
Extremely  
Beneficial 
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(e) 
 
(f) 
 
This next set of questions asks you to rate how other people in your life may feel about you doing 
exercise over the next month. Please pay careful attention to the words and descriptors at the 
end of each scale and circle the number that best represents how they might feel. Please answer 
all items from (a) to (c). 
 
I think that if I do exercise over the next month, most people who are important to me would 
be: 
 
(a) 
 
(b) 
 
(c) 
 
This next question asks you to rate how active (how much exercise) you think other people in 
your life are likely to do over the next month.  
 
I think that over the next month, most people who are important to me will themselves be: 
 
(a) 
This next set of questions asks you to rate how motivated you are to do exercise training over the 
next month. Pay careful attention to the words at the end of each scale and circle the number 
1 2 3 4 5 6 7 
Extremely 
Unimportant 
Quite 
Unimportant    
Slightly   
Unimportant 
Neutral Slightly  
Important 
Quite 
Important     
Extremely  
Important 
1 2 3 4 5 6 7 
Extremely 
Boring 
Quite 
Boring      
Slightly    
Boring 
Neutral Slightly  
Fun 
Quite 
Fun       
Extremely  
Fun 
1 2 3 4 5 6 7 
Extremely 
disapproving 
Quite 
disapproving      
Slightly    
disapproving 
Neutral Slightly  
approving 
Quite 
approving      
Extremely  
approving 
1 2 3 4 5 6 7 
Extremely 
discouraging 
Quite 
discouraging       
Slightly    
discouraging 
Neutral Slightly  
encouraging 
Quite 
encouraging       
Extremely  
encouraging 
1 2 3 4 5 6 7 
Extremely 
unsupportive  
Quite 
unsupportive       
Slightly    
unsupportive 
Neutral Slightly  
supportive 
Quite 
supportive       
Extremely  
supportive 
1 2 3 4 5 6 7 
Extremely 
inactive 
Quite 
inactive        
Slightly    
inactive 
Neutral Slightly  
active 
Quite 
active        
Extremely  
active 
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that best represents your level of motivation. 
 
(a) How motivated are you to do exercise over the next month? 
 
 
(b) I strongly intend to do everything I can to do exercise over the next month. 
 
 
(c) How committed are you to doing exercise over the next month? 
 
          
 
These next questions ask you to rate how likely you feel it is that you will be able to do exercise 
over the next month if you were really motivated. Pay careful attention to the words at the end 
of each scale and circle the number that best represents how you feel. 
 
If you were really motivated… 
(a) How controllable would it be for you to do exercise training over the next month? 
 
          
(b) How confident would you be that you could do exercise over the next month? 
 
 
 
 
 
 
1 2 3 4 5 6 7 
Extremely 
unmotivated 
Quite 
unmotivated         
Slightly    
unmotivated 
Neutral Slightly  
motivated 
Quite 
motivated       
Extremely  
motivated 
1 2 3 4 5 6 7 
Strongly 
disagree 
Moderately 
disagree   
Slightly       
disagree 
Neutral Slightly 
agree 
Moderately   
agree   
Strongly  
agree 
1 2 3 4 5 6 7 
Extremely 
uncommitted 
Quite 
uncommitted         
Slightly    
uncommitted 
Neutral Slightly  
committed 
Quite 
committed      
Extremely  
committed 
1 2 3 4 5 6 7 
Extremely 
uncontrollable 
Quite 
uncontrollable         
Slightly    
uncontrollable 
Neutral Slightly  
controllable 
Quite 
controllable      
Extremely  
controllable 
1 2 3 4 5 6 7 
Extremely 
unconfident 
Quite 
unconfident          
Slightly    
unconfident 
Neutral Slightly  
confident 
Quite 
confident      
Extremely  
confident 
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(c) Do you feel that whether or not you do exercise over the next month would be completely 
up to you? 
 
 
(d) How easy or difficult would it be for you to do exercise training over the next month? 
 
 
(e) Do you feel you would have complete control over whether or not you do exercise over 
the next month? 
 
 
(f) How certain or uncertain would you be that you could do exercise over the next month? 
 
 
 
 Do you have a specific plan for where, when, and how you are going to exercise over the next 
month?  
 
 
 
 
 
 
 
 
  
  
1 2 3 4 5 6 7 
Strongly 
disagree 
Moderately 
disagree   
Slightly       
disagree 
Neutral Slightly 
agree 
Moderately   
agree   
Strongly 
agree 
1 2 3 4 5 6 7 
Extremely 
difficult 
Quite 
difficult         
Slightly    
difficult 
Neutral Slightly  
easy 
Quite 
  easy       
Extremely  
easy 
1 2 3 4 5 6 7 
Strongly 
disagree 
Moderately 
disagree   
Slightly       
disagree 
Neutral Slightly 
agree 
Moderately   
agree   
Strongly 
agree 
1 2 3 4 5 6 7 
Extremely 
uncertain 
Quite 
uncertain        
Slightly    
uncertain 
Neutral Slightly  
certain 
Quite 
certain 
Extremely  
certain 
1 2 3 4 5 
Not at all A little bit   Somewhat Quite a bit Very much 
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END OF QUESTIONNAIRE PACK 
 
Thank you very much for your time and contribution to 
this important research! 
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DATA COLLECTION SHEET  
    
 
1.        Informed Consent        GP Consent   Demographic Info & Health 
History 
2. Medical History:  (conditions that may impact function/require tests to be modified)  
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
3. Body Composition: 
Height:  _____________cm    Weight: ______________kg  BMI: ___________ (kg/m2) 
4. Circumferences:  Min of 2 trials with the 3rd trial necessary if a 2mm difference between trials 
Waist:  ____________cm  ____________cm   ____________cm 
Hip: _____________cm  ____________cm   ____________cm 
 
5. DEXA full body scan:  remove shoes, socks, ALL metal (jewellery, underwire bra) and any 
prosthetics 
 Completed        
PQCT scan:      Tibia Length (left):  ________________ 
 Completed 
6. Resting Blood Pressure & HR:  (taken after resting in a supine position for 5 minutes)Blood 
Pressure: _____________mmHg   _____________mmHg _____________mmHg      
Heart Rate: _____________bpm  _____________bpm  _____________bpm 
7. 6m Walk Tests:  
 Normal:       _______sec      _______sec       _______sec      BEST: _______sec 
 Fast:           _______sec      _______sec       _______sec      BEST: _______sec 
 Backwards: _______sec      _______sec       _______sec      BEST: _______sec 
ID No: _____________ Initials:  __________ 
Date: ___________________ 
   Familiarization 
   Baseline 
Assessor: 
Appendix R – Data collection Sheet 
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8. 400 meter Walk:  
 Heart rate:  Before test: _______ bpm   Immediately after:   _______ bpm 
           1 minute after: _______ bpm   2 minutes after:  _______ bpm 
     
Warm-up Lap (“walk from 1 marker to the other in as few strides as possible”) 
 Number of strides: (for initial 20 meters) _______ 
  
 Laps:  1     2     3     4     5     6     7     8     9     10 400m Walk Time: ______________ 
 
 
9. Repeated Chair Rise:  2min rest between trials 
Trial 1: _________sec      Trial 2: _________sec      Trial 3: _________sec   BEST: _________sec  
 
10. Strength Testing 
a. 1 RM horizontal Chest Press: 
 Bar Start: _________________  Pillow Used: _______________ 
 Bench Position: ____________cm  Step Height: _______________ 
 Grip Distance: _____________cm   
 
Warm-up:  6 x 60% 1RM = ________kg (2min)   3 x 80% 1RM = ________kg (2min) 
 
1RM Attempts:  Trial 1: __________kg (2min)  Trial 2: __________kg (2min)  
Trial 3: __________kg (2min)  Trial 4: __________kg (2min)  
Trial 5: __________kg   Actual 1RM = ___________kg 
NOTES:  
______________________________________________________________________________ 
_______________________________________________________________________________ 
 
b. 1 RM single Leg Extension: (Alternate legs)            
Back Rest: ____________________  Leg Rest: ____________________ 
Lifting Arm (Knees at 90⁰): _________________ 
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RIGHT LEG LEFT LEG 
Warm-up: 6 x 60% 1RM = ________kg (2min) Warm-up: 6 x 60% 1RM = ________kg (2min) 
                   3 x 80% 1RM = ________kg (2min)                     3 x 80% 1RM = ________kg (2min)
1RM Attempts: Trial 1: __________kg (2min) 1RM Attempts: Trial 1: __________kg (2min) 
                             Trial 2: __________kg (2min)                              Trial 2: __________kg (2min) 
                             Trial 3: __________kg (2min)                              Trial 3: __________kg (2min) 
                             Trial 4: __________kg (2min)                              Trial 4: __________kg (2min) 
                             Trial 5: __________kg                                Trial 5: __________kg 
                            Actual 1RM = ___________kg                               Actual 1RM = __________kg
NOTES:  
______________________________________________________________________________ 
_______________________________________________________________________________ 
c. Hand Grip Dynamometer: (Alternate hands – 20-30 sec rest between trails) 
RIGHT HAND LEFT HAND 
Trial 1: _________kg       Trial 1: _________kg       
Trial 2: _________kg       Trial 2: _________kg       
Trial 3: _________kg       Trial 3: _________kg       
Mean of three : ___________kg Mean of three: ___________kg 
 
11. Questionnaires: (n/a for familiarization) 
  Completed all questions 
 
12. Collect/Give out:  
Familiarization Baseline 
Give out: Collect:   
 Questionnaires 
 ActiGraph Monitor 
 Explain ActiGraph Instructions 
 
 ActiGraph Monitor 
 Questionnaires 
NOTES:  
_______________________________________________________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________
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Signed declarations from all co-authors of papers to confirm that I, Christelle 
Schofield, contributed as significant manuscript writer and was responsible for all 
data acquisition, as well as the majority of data analysis and interpretation. 
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